<SEC-DOCUMENT>0001178913-23-002362.txt : 20230703
<SEC-HEADER>0001178913-23-002362.hdr.sgml : 20230703
<ACCEPTANCE-DATETIME>20230703154940
ACCESSION NUMBER:		0001178913-23-002362
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20230703
FILED AS OF DATE:		20230703
DATE AS OF CHANGE:		20230703

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813676773
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		231065160

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2329929.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="text-align: center; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;"><br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES<br>
        SECURITIES AND EXCHANGE COMMISSION</font><br>
      Washington, D.C. 20549</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>
      UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">For the month of July 2023</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number 001-38807</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">CHEMOMAB THERAPEUTICS LTD.</font><br>
      (Translation of registrant&#8217;s name into English)</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;&#160;&#160;__</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;&#160;&#160;__</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Chemomab Therapeutics Ltd. (the &#8220;Company&#8221;) hereby furnishes the following documents:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z976a335d958d4a168d5a082b78bcf9d7">

        <tr>
          <td style="width: 3.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.08%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">(i)</a></div>
          </td>
          <td style="width: 94.8%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Notice and Proxy Statement&#160;with respect to the Company&#8217;s annual general meeting of
                the shareholders (the &#8220;Meeting&#8221;) to be held on August 7, 2023, describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting.</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8220de2f286f4c0282e0fa64d4e2f303">

        <tr>
          <td style="width: 3.12%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2.08%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-2.htm">(ii)</a></div>
          </td>
          <td style="width: 94.8%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-2.htm">Proxy Card&#160;whereby holders of American Depository Shares of the Company may vote at
                the Meeting without attending in person.</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This Form 6-K is incorporated by reference into the Company&#8217;s Registration Statements on Form S-3 (File No.&#160;333-255658) and Form S-8 (File No. 333-259489, and No.&#160;333-266868).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; text-align: center;">- 2 -<br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURE</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z849ce90edc5f4235b8e86d6f497ccf42">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Date: July 3, 2023</div>
          </td>
          <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 46%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Sigal Fattal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Financial Officer&#160;&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center;">- 3 -</div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <br>
    <div class="BRPFPageFooter">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 99.1</u></div>
    <div style="text-align: center; line-height: 1.25;"><img width="313" height="88" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: right; line-height: 1.25;">July 3, 2023</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Dear Chemomab Therapeutics Ltd. Shareholders:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cordially invite you to attend the Annual General Meeting of Shareholders (the &#8220;<font style="font-weight: bold; font-style: italic;">Meeting</font>&#8221;) of Chemomab Therapeutics
      Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), to be held on August 7, 2023 at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company&#8217;s notice of the Meeting, as published on July 3, 2023, and the proxy statement appearing on the following pages, describe in detail the matters to be acted upon at the
      Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Meeting, shareholders will be asked to consider and vote on the matters listed in the enclosed Notice of Annual General Meeting of Shareholders. Our board of directors
      recommends that you vote&#160;<font style="font-weight: bold;">FOR</font>&#160;each of the proposals listed in the notice.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Only shareholders of record at the close of business on July 3, 2023 are entitled to notice of and to vote at the Meeting or any postponement or adjournment thereof.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">
        <div style="text-indent: 36pt; line-height: 1.25;">We look forward to greeting personally those shareholders who are able to be present at the Meeting;&#160;<font style="font-weight: bold;">however, whether or not you plan to attend in person, it is
            important that your shares be represented</font>. Holders of our American Depositary Shares (&#8220;<font style="font-weight: bold; font-style: italic;">ADSs</font>&#8221;) will receive voting instruction cards either electronically or by physical mail,
          depending on the delivery instructions such holder has provided to its bank or broker. The voting instruction cards will be distributed by Broadridge Financial Solutions or each holder&#8217;s bank or broker on behalf of the Bank of New York Mellon,
          the depositary of the ADSs, and the voting instruction cards will enable them to instruct the Bank of New York Mellon on how to vote the Company&#8217;s ordinary shares represented by their ADSs with regard to the proposals listed in the Notice of
          Annual Meeting of Shareholders.&#160;<font style="font-weight: bold;">Accordingly, please sign and date the voting instruction card at your earliest convenience and either submit it electronically using the instructions enclosed or mail it in the
            envelope provided.</font></div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We look forward to greeting as many of you as can attend the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z768a8c7027254b23a45538c4ff4f8501" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.08%; vertical-align: top;">
            <div style="line-height: 1.25;">Sincerely,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.08%; vertical-align: top;">
            <div style="line-height: 1.25;">/s/ Dr. Nissim Darvish</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.92%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.08%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairperson of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="313" height="88" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Notice of Annual General Meeting of Shareholders</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">To be Held on August 7, 2023</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Dear Chemomab Therapeutics Ltd. Shareholders:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We cordially invite you to attend the Annual General Meeting of shareholders (the &#8220;<font style="font-weight: bold; font-style: italic;">Meeting</font>&#8221;) of Chemomab Therapeutics
      Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), to be held on August 7, 2023 at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following matters are on the agenda for the Meeting:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z5e41975597b64c439e02c22d1f9ab744" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(1)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To re-elect each of Dr. Claude Nicaise and Mr. Neil Cohen as Class II directors, to hold office until the close of the Company&#8217;s annual general meeting of shareholders in 2026, and until
              their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the Companies Law;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z895fb06ad44f4e4bbb920da19ea82cfe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To approve an amendment to the compensation terms of Dr. Adi Mor in connection with her appointment as the Company&#8217;s Chief Executive Officer;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z3dd60177bb1f4f05accc9f31dc6df7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(3)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To approve amendments to the compensation terms of the non-executive members of the Board of Directors of the Company;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(4)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2023 and
              until the Company&#8217;s next annual general meeting of shareholders, and to authorize the Company&#8217;s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to considering and voting on the foregoing proposals (the &#8220;<font style="font-weight: bold; font-style: italic;">Proposals</font>&#8221;), members of the Company&#8217;s management
      will be available at the Meeting to discuss the consolidated financial statements of the Company for the fiscal year ended December 31, 2022.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You are entitled to receive notice of, and vote at, the Meeting if you are a shareholder of record at the close of business on July 3, 2023, in person or through a broker, trustee
      or other nominee that is one of our shareholders of record at such time, or which appear in the participant listing of a securities depository on that date.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">
      <div style="text-indent: 35.5pt; line-height: 1.25; font-family: 'Times New Roman', serif;">We look forward to greeting personally those shareholders who are able to be present at the Meeting;&#160;<font style="font-weight: bold;">however, whether or not
          you plan to attend in person, it is important that your shares be represented</font>. Holders of our American Depositary Shares, each representing twenty (20) ordinary shares of no par value (&#8220;<font style="font-weight: bold; font-style: italic;">ADSs</font>&#8221;)


        will receive voting instruction cards either electronically or by physical mail, depending on the delivery instructions such holder has provided to its bank or broker. The voting instruction cards will be distributed by Broadridge Financial
        Solutions or each holder&#8217;s bank or broker on behalf of the Bank of New York Mellon, the depositary of the ADSs, and the voting instruction cards will enable them to instruct the Bank of New York Mellon on how to vote the Company&#8217;s ordinary shares
        represented by their ADSs with regard to the proposals listed in the Notice of Annual Meeting of Shareholders.&#160;<font style="font-weight: bold;">Accordingly, please sign and date the voting instruction card at your earliest convenience and either
          submit it electronically using the instructions enclosed or mail it in the envelope provided.</font></div>
    </div>
    <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Our Board of Directors unanimously recommends that you vote &#8220;FOR&#8221; each of the above Proposals, which are described in the accompanying proxy
      statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least 25% of the voting power of the ADSs constitutes a quorum for purposes of
      the Meeting. If such quorum is not present within half an hour from the time scheduled for the Meeting, the Meeting will be adjourned to the following week (to the same day, time and place or to a specified day, time and place). At such adjourned
      meeting the presence of at least one or more shareholders in person or by proxy (regardless of the voting power represented by their ADSs) will constitute a quorum.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Section 66(b) of the Israeli Companies Law, 5759-1999 (the &#8220;<font style="font-weight: bold; font-style: italic;">Companies Law</font>&#8221;) allows shareholders who hold at least 1% of
      our outstanding voting power to submit a request to include a proposal on the agenda of a general meeting of our shareholders. Such request made by an eligible shareholder must be received by us no later than July 10, 2023. A copy of the proxy
      statement (which includes the full version of the proposed resolutions) and a proxy card is being distributed to shareholders and also furnished to the U.S. Securities and Exchange Commission, under cover of Form 6-K. Shareholders are also able to
      review the proxy statement at the &#8220;<font style="font-style: italic;">Investor Relations</font>&#8221; portion of our website&#160;<u>https://investors.chemomab.com/</u> or at our headquarters at Kiryat Atidim, Building 7, Tel Aviv,&#160;Israel 6158002, upon prior
      notice and during regular working hours (telephone number: +972-77-331-0156) until the date of the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 34.75pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented at the Meeting in person or by proxy and voting thereon is necessary for the approval of each
        proposal; provided however that the approval of Proposal&#160;No. 2 is subject to the fulfillment of one of the following additional voting requirements:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z00d868e9eaa04b2ea533f01e34120239" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">(i)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">a majority of the shares that are voted at the Meeting in favor of the proposal, excluding abstentions, includes a majority of the votes of shareholders present and voting who are not
              controlling shareholders or do not have a personal interest in the approval of the proposal; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z15eda390536640d2b0877062a45f9f4d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">(ii)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the total number of shares held by the shareholders mentioned in clause (i) above that are voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in the
              Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">A &#8220;<font style="font-weight: bold; font-style: italic;">controlling shareholder</font>&#8221; is defined as any shareholder that has the ability to direct the company&#8217;s activities
        (other than by means of being a director or office holder (as defined in the Israeli Companies Law) of the company), including, with respect to Proposal No. 2, a person who holds 25% or more of the voting rights in the general meeting of the
        company if there is no other person who holds more than 50% of the voting rights in the company.&#160; Two or more persons holding voting rights in the company each of which has a personal interest in the approval of the transaction being brought for
        approval of the company will be considered to be joint holders. A person is presumed to be a controlling shareholder if it holds or controls, by himself or together with others, one half or more of any one of the &#8220;means of control&#8221; of the company.
        &#8220;<font style="font-weight: bold; font-style: italic;">Means of control</font>&#8221; is defined as any one of the following: (i) the right to vote at a general meeting of the company, or (ii) the right to appoint directors of the company or its chief
        executive officer.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">A &#8220;<font style="font-weight: bold; font-style: italic;">personal interest</font>&#8221; of a shareholder in an action or transaction of a company includes (i) a personal interest of
        any of the shareholder&#8217;s relative (i.e. spouse, brother or sister, parent, grandparent, child as well as child, brother, sister or parent of such shareholder&#8217;s spouse or the spouse of any of the above) or an interest of a company with respect to
        which the shareholder or the shareholder&#8217;s relative (as detailed above) holds 5% or more of such company&#8217;s issued shares or voting rights, in which any such person has the right to appoint a director or the chief executive officer or in which any
        such person serves as a director or the chief executive officer, including the personal interest of a person voting pursuant to a proxy whether or not the proxy grantor has a personal interest; and (ii) excludes an interest arising solely from the
        ownership of ADSs or ordinary shares of the company.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25; font-weight: bold;">If you do not state whether or not you are a controlling shareholder or do not confirm whether or not you have personal interest, as applicable, your shares
        will&#160;<u>not</u>&#160;be voted for Proposal No. 2.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z9d827d25a6024735b89bd19f24b4baf0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;By Order of the Board of Directors</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">/s/ Dr. Nissim Darvish</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairperson of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">Dated: July 3, 2023</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: center;">&#160;- ii -<br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="313" height="88" src="image0.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Chemomab Therapeutics Ltd.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proxy Statement</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">______________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Annual General Meeting of Shareholders</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">To Be Held on August 7, 2023</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This proxy statement is being furnished in connection with the solicitation of proxies on behalf of the board of directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221;) of Chemomab Therapeutics Ltd. (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221; or &#8220;<font style="font-weight: bold; font-style: italic;">Chemomab</font>&#8221;) to be voted at the 2023 Annual General
      Meeting of Shareholders (the &#8220;<font style="font-weight: bold; font-style: italic;">Meeting</font>&#8221;), and at any adjournment or postponement thereof, pursuant to the accompanying Notice of Annual General Meeting of Shareholders. The Meeting will be
      held on August 7, 2023, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This proxy statement, the attached notice of annual general meeting of shareholders and the enclosed proxy card or voting instruction form, as applicable, are being made available
      to holders of the Company&#8217;s American Depositary Shares (&#8220;<font style="font-weight: bold;">ADSs</font>&#8221;), each representing twenty (20) ordinary shares of no par value (&#8220;<font style="font-weight: bold;">ordinary shares</font>&#8221;), on July 3, 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You are entitled to receive notice of, and vote at, the Meeting if you are a shareholder of record at the close of business on July 3, 2023, in person or through a broker, trustee
      or other nominee that is one of our shareholders of record at such time, or which appear in the participant listing of a securities depository on that date. You can vote your Shares by attending the Meeting or by following the instructions under &#8220;<font style="font-style: italic;">How You Can Vote</font>&#8221; below. Our Board urges you to vote your ADSs so that they will be counted at the Meeting or at any postponements or adjournments of the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Agenda Items</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following matters are on the agenda for the Meeting:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z928c2997a12a4e3f9b2cb999b733f10c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(1)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To re-elect each of Claude Nicaise and Neil Cohen as Class II directors, to hold office until the close of the Company&#8217;s annual general meeting of shareholders in 2026, and until their
              respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the Companies Law;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z5d76369f7f034df38359c3cb86534310" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To approve an amendment to the compensation terms of Dr. Adi Mor in connection with her appointment as the Company&#8217;s Chief Executive Officer;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z9f626c10a7c24c269b2e4bec476736a6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(3)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To approve amendments to the compensation terms of the non-executive members of the Board of Directors of the Company;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z4f40eafd60a741dca347c6635e1153c4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(4)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2023 and
              until the Company&#8217;s next annual general meeting of shareholders, and to authorize the Company&#8217;s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to considering and voting on the foregoing proposals (the &#8220;<font style="font-weight: bold; font-style: italic;">Proposals</font>&#8221;), members of the Company&#8217;s management
      will be available at the Meeting to discuss the consolidated financial statements of the Company for the fiscal year ended December 31, 2022.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are not aware of any other matters that will come before the Meeting. If any other matters are presented properly at the Meeting, the persons designated as proxies intend to
      vote upon such matters in accordance with their best judgment and the recommendation of the Board.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Board Recommendations</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-style: italic; font-weight: bold;">Our Board unanimously recommends that you vote &#8220;FOR&#8221; each of the above Proposals.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Quorum and Adjournment</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">On July 3, 2023, we had a total of 11,818,473 ADSs issued and outstanding (one ADS represents 20 Ordinary Shares).&#160; Each ADS outstanding as of the close of
        business on July 3, 2023, is entitled to one vote on each of the Proposals to be presented at the Meeting.&#160; Under our amended and restated articles of association (the &#8220;<font style="font-weight: bold; font-style: italic;">Articles of Association</font>&#8221;),


        the Meeting will be properly convened if at least two shareholders attend the Meeting in person or sign and return proxies, provided that they hold, in the aggregate, voting power representing at least 25% of our voting power.&#160; If such quorum is
        not present within half an hour from the time scheduled for the Meeting, the Meeting will be adjourned to the following week (to the same day, time and place or to a specified day, time and place). At such adjourned meeting the presence of at least
        one or more shareholders in person or by proxy (regardless of the voting power represented by their ADSs) will constitute a quorum.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Abstentions and &#8220;broker non-votes&#8221; are counted as present and entitled to vote for purposes of determining a quorum. A &#8220;broker non-vote&#8221; occurs when a bank, broker or other holder
      of record holding ordinary shares for a beneficial owner attends the shareholder meeting but does not vote on a particular proposal because that holder does not have discretionary voting power for that particular item and has not received
      instructions from the beneficial owner. Brokers that hold ordinary shares in &#8220;street name&#8221; for clients (as described below) typically have authority to vote on &#8220;routine&#8221; proposals even when they have not received instructions from beneficial owners.
      The only item on the Meeting agenda that may be considered routine is Proposal No. 5 relating to the reappointment of the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2023; however, we cannot be
      certain whether this will be treated as a routine matter since our proxy statement is prepared in compliance with the Israeli Companies Law 5759-1999 (the &#8220;<font style="font-weight: bold; font-style: italic;">Companies Law</font>&#8221;), rather than the
      rules applicable to domestic U.S. reporting companies. Therefore, it is important for a shareholder that holds ADSs through a bank or broker to instruct its bank or broker how to vote its ordinary shares, if the shareholder wants its ADSs to count
      for the Proposals set forth in this proxy statement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Vote Required for Approval of Each of the Proposals</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 34.75pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the voting power represented and voting in person or by proxy is required to approve each of the Proposals set forth in
        this proxy statement; provided however that the approval of Proposal&#160;No. 2 is subject to the fulfillment of one of the following additional voting requirements:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="za2dcacc0e1df4f5c87e32ec82e4806d8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">(i)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">a majority of the shares that are voted at the Meeting in favor of the proposal, excluding abstentions, includes a majority of the votes of shareholders present and voting who are not
              controlling shareholders or do not have a personal interest in the approval of the proposal; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4b41e719e2984203b4c1eea5c9719f6d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: top;">
            <div style="line-height: 1.25;">(ii)</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">the total number of shares held by the shareholders mentioned in clause (i) above that are voted against the proposal does not exceed two percent (2%) of the aggregate voting rights in the
              Company.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">A &#8220;<font style="font-weight: bold;">controlling shareholder</font>&#8221; is defined as any shareholder that has the ability to direct the company&#8217;s activities (other than by means
        of being a director or office holder (as defined in the Israeli Companies Law) of the company), including, with respect to Proposal No. 2, a person who holds 25% or more of the voting rights in the general meeting of the company if there is no
        other person who holds more than 50% of the voting rights in the company.&#160; Two or more persons holding voting rights in the company each of which has a personal interest in the approval of the transaction being brought for approval of the company
        will be considered to be joint holders. A person is presumed to be a controlling shareholder if it holds or controls, by himself or together with others, one half or more of any one of the &#8220;means of control&#8221; of the company. &#8220;<font style="font-weight: bold;">Means of control</font>&#8221; is defined as any one of the following: (i) the right to vote at a general meeting of the company, or (ii) the right to appoint directors of the company or its chief executive officer.</div>
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.5pt; line-height: 1.25;">A &#8220;<font style="font-weight: bold;">personal interest</font>&#8221; of a shareholder in an action or transaction of a company includes (i) a personal interest of any of the
        shareholder&#8217;s relative (i.e. spouse, brother or sister, parent, grandparent, child as well as child, brother, sister or parent of such shareholder&#8217;s spouse or the spouse of any of the above) or an interest of a company with respect to which the
        shareholder or the shareholder&#8217;s relative (as detailed above) holds 5% or more of such company&#8217;s issued shares or voting rights, in which any such person has the right to appoint a director or the chief executive officer or in which any such person
        serves as a director or the chief executive officer, including the personal interest of a person voting pursuant to a proxy whether or not the proxy grantor has a personal interest; and (ii) excludes an interest arising solely from the ownership of
        ADSs or ordinary shares of the company.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">If you do not state whether or not you are a controlling shareholder or do not confirm whether or not you have personal interest, as applicable, your shares
      will&#160;<u>not</u>&#160;be voted for Proposal No. 2.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The proxy card or voting instruction card includes Item 2A, under which you should mark &#8220;YES&#8221; in order to confirm that you are&#160;<font style="font-weight: bold;"><u>not</u></font>&#160;a
      controlling shareholder and do&#160;<font style="font-weight: bold;"><u>not</u></font>&#160;have a personal interest in the approval of the proposal. In the alternative, if you believe that you are a controlling shareholder or have such a personal interest in
      the approval of the proposal, you should mark the box &#8220;NO&#8221; in Item 1A when you mark your vote with respect to the proposal.&#160;<font style="font-weight: bold;">If you do not mark any box in Item 2A, your vote will not be counted on the proposal.</font>&#160;If





      you are unsure whether you are a controlling shareholder or have a personal interest in the proposal, please contact the Company&#8217;s Chief Financial Officer, Sigal Fattal, at&#160;<u>sigal.fattal@chemomab.com</u>, or, if you hold your ADSs in &#8220;street name,&#8221;
      you may also contact the representative managing your account, who would then contact us on your behalf.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Abstentions and &#8220;broker non-votes&#8221; are counted as present and entitled to vote for purposes of determining a quorum. Apart from for the purpose of determining a quorum, broker
      non-votes will not be counted as present and are not entitled to vote. Abstentions will not be treated as either a vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; or &#8220;<font style="font-weight: bold;">AGAINST</font>&#8221; a matter.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On each matter submitted to the shareholders for consideration at the Meeting, only ADSs that are voted on such matter will be counted toward determining whether shareholders
      approved the matter. ordinary shares present at the Meeting that are not voted on a particular matter (including broker non-votes) will not be counted in determining whether such matter is approved by shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the terms of the Deposity Agreement among the Company and The Bank of New York Mellon, as Depositary, and the holders of the ADSs, the Depositary shall endeavor (to the
      extent practicable and in accordance with applicable law and the Articles of Association) to vote or cause to be voted the number of Shares represented by ADSs in accordance with the instructions provided by the holders of ADSs to the Depositary. If
      no instructions are received by the Depositary from a holder of ADSs on or before the date established by the Depositary for such purpose, the Depositary will not exercise any discretion in voting the ADSs.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">How are My Votes Cast when I Sign and Return a Voting Instruction Card or Proxy Card?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">When you sign and submit a voting instruction card, you instruct your broker (or nominee that holds your ADSs of record) to vote your ADSs in a certain manner. When you sign a
      proxy card, you appoint Sigal Fattal, our Chief Financial Officer, as your representative at the Meeting. Your broker (or other nominee), in the case of ADSs held in street name, or Ms. Fattal, in the case of ADSs held by record shareholders, will
      ensure that your ADSs are voted at the Meeting as you have instructed them on the voting instruction card or proxy card (as applicable). Each of such persons may appoint a substitute for himself.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Even if you plan to attend the Meeting, it is a good idea to complete, sign and return your voting instruction card or proxy card in advance of the Meeting in case your plans
      change. This way, your ADSs will be voted by you whether or not you actually attend the Meeting.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">May I Revoke My Proxy?</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Shareholders may revoke the authority granted by their execution of proxies before the effective exercise thereof by filing with the
        Company a written notice of revocation or duly executed proxy bearing a later date, or by voting in person at the Meeting. However, if a shareholder attends the Meeting and does not elect to vote in person, his or her proxy will not be revoked.
        Unless otherwise indicated on the form of proxy, if a proxy is properly executed and received by the Company prior to the Meeting, ADSs represented by the proxy will be voted in favor of the matter to be presented to the Meeting, as described
        above.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">What if I Receive More than One Proxy Card?</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">You may receive more than one proxy card or voting instruction form if you hold ADSs in more than one account, which may be in
        registered form or held in street name. Please vote in the manner described under &#8220;How Do I Vote?&#8221; for each account to ensure that all of your ADSs are voted.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What if I do not Vote for the Matters Listed on My Proxy Card?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On all matters considered at the Meeting, abstentions of a holder of ADSs will be treated as neither a vote &#8220;for&#8221; nor a vote &#8220;against&#8221; the matter, although they will be counted in
      determining if a quorum is present.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Will My ADSs be Voted if I do not Return My Proxy Card and do not Attend the Annual General Meeting?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If your Shares are registered in your name or if you have share certificates, they will not be voted if you do not return your proxy card by mail or vote at the meeting as
      described above under &#8220;How Do I Vote?&#8221;.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If your ADSs are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your ADSs as described above under &#8220;How Do I Vote?,&#8221;
      the bank, broker or other nominee has the authority to vote your Shares on certain routine matters scheduled to come before the meeting even if it does not receive instructions from you. See &#8220;What are &#8220;broker non-votes&#8221; and what effect do they have
      on the proposals?&#8221; We encourage you to provide voting instructions. This ensures your Shares will be voted at the meeting in the manner you desire.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Is Voting Confidential?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Yes. Only the inspector of elections and our employees who have been assigned the responsibility for overseeing the legal aspects of the Meeting will have access to your proxy
      card. The inspector of elections will tabulate and certify the vote. Any comments written on the proxy card will remain confidential unless you ask that your name be disclosed.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">What are the Costs of Soliciting these Proxies?</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We will pay all of the costs of soliciting these proxies. Our officers, directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these
      employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We
      will then reimburse them for their expenses.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Could other Matters be Decided at the Meeting?</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We do not know of any other matters that will be considered at the Meeting. If any other matters arise at the Meeting at or by the direction of the Board, the proxies will be voted
      at the discretion of the proxy holders.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">What Happens if the Meeting is Postponed or Adjourned?</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Your proxy will still be valid and may be voted at the postponed or adjourned meeting. You will still be able to change or revoke
        your proxy until it is voted.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Where can I find the voting results of the Meeting?</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We will announce the results for the proposals voted upon at the Meeting in a Current Report on Form 6-K following the Meeting.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Where can I find additional copies of this proxy statement?</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Copies of this proxy statement are available on our website at https://www.chemomab.com/, under the Investor Relations tab (click on the &#8220;Investor
        Relations&#8221; link), and on the SEC website, <font style="font-style: italic;">www.sec.gov</font>.</div>
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">The beneficial ownership of ordinary shares is determined in accordance with the SEC rules and generally includes any ordinary shares over which a person
        exercises sole or shared voting or investment power. For purposes of the table below, we deem shares subject to options or warrants that are currently exercisable or exercisable within 60 days of July 3, 2023, to be outstanding and to be
        beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other
        person. The percentage of shares beneficially owned is based on 11,818,473 ADSs outstanding as of July 3, 2023.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z21ced8165deb4ab797ca4694c6dbca3e" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">NAME OF BENEFICIAL OWNER</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Total</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Beneficial</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ownership (ADSs)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage of</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADSs Beneficially</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Owned</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;">
            <div style="line-height: 1.25; font-style: italic;">5% and Greater Shareholders</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="line-height: 1.25;">OrbiMed Israel (1)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,270,091</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">19.2</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">The Centillion Fund(2)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">661,370</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5.6</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="line-height: 1.25;">Rivendell Investments 2017-9(3)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">1,131,563</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">9.6</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Kobi George(4)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">747,445</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">6.2</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="line-height: 1.25;">Apeiron Group(5)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">770,388</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">6.5</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25; font-style: italic;">Directors and Executive Officers</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Adi Mor (6)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">747,445</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">6.2</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Sigal Fattal (7)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">29,684</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Matthew Frankel (8)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Neil Cohen (9)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">27,081</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Nissim Darvish (10)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">27,716</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Alan Moses (11)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">16,393</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="line-height: 1.25;">Claude Nicaise (12)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">16,393</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="line-height: 1.25;">Jill Quigley (13)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,304</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">(</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">*)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%;">
            <div style="line-height: 1.25; font-weight: bold;">All current executive officers and directors as a group (8 persons)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">870,016</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">7.20</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">* Less than one percent (1%)</div>
    </div>
    <table cellspacing="0" cellpadding="1" border="0" id="z6af66b3a0e1a48c6b55adebbc3d37776" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(1)</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Pursuant to a Schedule 13D/A filed with the SEC by OrbiMed Israel BioFund GP Limited Partnership (&#8220;OrbiMed BioFund&#8221;) and OrbiMed Israel GP Ltd. (&#8220;OrbiMed GP&#8221;, and together with OrbiMed
              BioFund, &#8220;OrbiMed Israel&#8221;) on January 5, 2023, such amount consists of (i) 2,241,274 ADSs and (ii) 28,817 ADSs issuable upon the exercise of warrants to purchase ADSs. OrbiMed GP, a company that acts as general partner of certain limited
              partnerships, is the general partner of OrbiMed BioFund, which is the general partner of OrbiMed Israel Partners Limited Partnership, which is the entity that holds the foregoing securities. The address of OrbiMed Israel is 89 Medinat
              HaYehudim St., Build E, 11th Floor, Herzliya 46766 Israel.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(2)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The address of Centillion Fund, Inc. is 10 Manoel Street, Castries, Saint Lucia.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(3)</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Represents 1,108,509 ADSs, representing 22,170,180 ordinary shares, held by Rivendell Investments 2017-9 LLC, or Rivendell, as reported by Rivendell on Schedule 13G filed with the SEC on
              March 26, 2021, and 23,054 ADSs, representing 461,080 ordinary shares, issuable upon the exercise of warrants. Rivendell is the shareholder of record. Peter Thiel is the beneficial owner of Rivendell and has sole voting and investment power
              over the securities held by Rivendell. The address of Rivendell is 1209 Orange Street, Wilmington, Delaware 19801.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(4)</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="line-height: 1.25;"><font style="line-height: 1.25;"></font>
              <div style="text-align: justify; line-height: 1.25;">Consists of (i) 257,247 ADSs owned directly by Dr. George, (ii) 324,775 ADSs owned by Dr. Adi Mor (Dr. George&#8217;s spouse), (iii) 33,725 options to purchase 33,725 ADSs issued directly to Dr.
                George, issuable upon the exercise of options, and (iv) 131,698 options to purchase 131,698 ADSs, issued to Dr. Mor, (Dr. George&#8217;s spouse), as reported by Dr. Adi Mor on Schedule 13D/A filed with the SEC on November 17, 2022</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(5)</div>
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">The Apeiron Group consists of (i) Apeiron SICAV Ltd. - Presight Capital Fund One, of which owns 438,993 ADSs, (ii) Apeiron Presight Capital Fund II, LP, of which owns 288,170 ADSs and 28,817
              ADSs issuable upon the exercise of warrants and (iii) Apeiron Investment Group Ltd., of which owns 14,408 ADSs issuable upon the exercise of warrants. Each of Fabian Hansen and Christian Angermayer may be deemed to share voting and investment
              power with respect to the ADSs held by the Apeiron Group.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(6)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Consists of (i) 324,775 ADSs owned directly by Dr. Mor, (ii) 257,247 ADSs owned by Dr. George, (Dr. Mor&#8217;s spouse), (iii) 131,698 ADSs issued to Dr. Mor, issuable upon the exercise of options
              within 60 days of the date hereof, and (iv) 33,725 options to purchase 33,725 ADSs issued to Dr. George, (Dr. Mor&#8217;s spouse) issuable upon the exercise thereof within 60 days of the date hereof, as reported by Dr. Adi Mor on Schedule 13D/A
              filed with the SEC on November 17, 2022</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(7)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Includes 5,209 ADSs, and 24,475 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Ms. Sigal Fattal on Form 4 filed with the SEC on June 16, 2023.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(8)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">No options have vested or expected to vest within 60 days of the date hereof, as reported by Dr. Matthew Frankel on Form 3 filed with the SEC on November 15, 2022.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(9)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Includes 10,000 ADSs, and 17,081 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Mr. Neil Cohen on Form 4 filed with the SEC on March 23, 2023.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(10)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Includes 1,200 ADSs, and 26,516 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Nissim Darvish on Form 4 filed with the
              SEC on March 23, 2023.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(11)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Represents 16,393 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Alan Moses on Form 4 filed with
              the SEC on March 23, 2023.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(12)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Represents 16,393 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Dr. Claude Nicaise on Form 4 filed with the SEC on March 23, 2023.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.37%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">(13)</div>
          </td>
          <td style="width: 95.63%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Represents 5,304 ADSs issuable upon the exercise of options within 60 days of the date hereof, as reported by Ms. Jill Quigley on Form 4 filed with the SEC on June 20, 2023.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">COMPENSATION OF EXECUTIVE OFFICERS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">For information concerning the annual compensation earned during fiscal year ended December 31, 2022 by our five (5) most highly compensated executive officers see Part III,
      Item 11 &#8220;Executive Compensation&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 20, 2023 (the &#8220;<font style="font-weight: bold; font-style: italic;">Annual Report</font>&#8221;), a copy of which is
      available on our website at https://investors.chemomab.com/sec-filings.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-variant: small-caps; font-weight: bold;">CORPORATE GOVERNANCE</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Overall Role of the Board and Board Leadership Structure</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 25.5pt; line-height: 1.25;">Under the Companies Law, our Board is responsible for setting our general policies and supervising the performance of management. Our Board may exercise all powers and may take
      all actions that are not specifically granted by the Companies Law or our Articles of Association to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities
      established by our Board.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 25.5pt; line-height: 1.25;">Under the Companies Law, the chief executive officer of a public company, or a relative of the chief executive officer, may not serve as the chairperson of the board of directors
      of such public company, and the chairperson of the board of directors of a public company, or a relative of the chairperson, may not be vested with authorities of the chief executive officer of such public company without obtaining shareholder
      approval pursuant to special majority requirements set forth in the Companies Law. Our current chairperson of the Board, Dr. Nissim Darvish, assumed such role on June 1, 2023.</div>
    <div style="text-align: justify; text-indent: 25.5pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 25.5pt; line-height: 1.25;">Our Board is currently composed of six (6) members. Our Board consists of three classes of directors, each serving staggered three-year terms. Upon expiration of the term of a
      class of directors, directors in that class will be elected for a three-year term at the annual general meeting of shareholders in the year in which that term expires. Each director&#8217;s term continues until the election and qualification of his or her
      successor, or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Role of the Board in Risk Oversight</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 34.5pt; line-height: 1.25;">Our Board is responsible for overseeing our risk management process. Our Board focuses on our general risk management strategy, the most significant risks facing us, and oversees
      the implementation of risk mitigation strategies by management. Our Board is also apprised by management of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions.
      The Board&#8217;s independent oversight function is further enhanced by the fact that all of the Board&#8217;s Committees are composed entirely of independent directors, the directors have complete access to management and the Board and its committees may retain
      their own respective advisors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Corporate Governance Guidelines</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 30.7pt; line-height: 1.25;">Our Board strongly supports effective corporate governance and has developed and followed a program of strong corporate governance. Our corporate governance and nominating
      committee is responsible for overseeing our guidelines and reporting and making recommendations to the Board concerning corporate governance matters. Our guidelines are published on our website at https://investors.chemomab.com/documents and are
      available in print to any shareholder who requests them from our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Director Independence</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25;">Based upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our Board has determined that each of
          the directors is independent as defined under Nasdaq listing standards, with the exception of Dr. Mor, our Chief Executive Officer and Chief Scientific Officer. Our Board also determined that Nissim Darvish and Neil Cohen, who comprise both the
          compensation committee and the corporate governance and nominating committee, each satisfy the independence standards for such committees established by the SEC and Nasdaq listing standards, as applicable. With respect to the audit committee, our
          Board has determined that Jill Quigley, Claude Nicaise and Alan Moses satisfy the independence standards for such committee established by Rule&#160;10A-3&#160;under the&#160;Exchange Act, the SEC and Nasdaq listing standards, as applicable, and that Jill
          Quigley is a financial expert under the rules of the SEC. The Board considered the relationships between such directors and certain of the investors of the Company and determined that such relationships did not affect such directors&#8217; independence
          under the standards of Nasdaq, or, where applicable, under SEC rules.</div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Code of Business Conduct and Ethics</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have adopted a Code of Business Conduct and Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors are
      bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to the audit committee. The Code of Business Conduct and Ethics includes provisions applicable to all of our employees, including
      senior financial officers and members of our Board and is posted on our website (<font style="font-style: italic;">https://investors.chemomab.com/</font>). We intend to post amendments to or waivers from any such Code of Business Conduct and Ethics.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Other Policies</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our insider trading and blackout policy prohibits directors, officers and employees from engaging in transactions in publicly traded options, such as puts and calls, and other
      derivative securities with respect to our securities. This prohibition extends to any hedging or similar transactions designed to decrease the risks associated with holding our securities.</div>
    <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Board Meetings</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">The Board meets regularly during the year and holds special meetings and acts by unanimous written consent whenever circumstances require. Independent directors meet at regular executive sessions
        without management present. During fiscal year 2022, the Board held 12 meetings and conducted certain business by unanimous consent. All of our directors are encouraged to attend the Meeting. Each of our directors attended 100%&#160; of the aggregate of
        the total number of meetings of the Board and the total number of meetings held by all committees of the Board on which such director served. Directors are expected to attend the Meeting.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Board Committees</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Board has established the following committees. Each committee operates in accordance with a written charter that sets forth the committee&#8217;s structure, operations, membership
      requirements, responsibilities and authority to engage advisors.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Audit Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law, the&#160;Exchange Act&#160;and Nasdaq rules, we are required to establish an audit committee, and we have a separately-designated standing audit committee
      established in accordance with section 3(a)(58)(A) of the Exchange Act.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The responsibilities of an audit committee under the Companies Law include identifying and addressing flaws in the business management of the company, reviewing and approving
      related party transactions, establishing whistleblower procedures, overseeing the company&#8217;s internal audit system and the performance of its internal auditor, and assessing the scope of the work and recommending the fees of the company&#8217;s independent
      accounting firm. In addition, the audit committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and to
      establish procedures for considering proposed transactions with a controlling shareholder.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with U.S. law and Nasdaq requirements, our audit committee is also responsible for the appointment, compensation and oversight of the work of our independent auditors
      and for assisting our Board in monitoring our financial statements, the effectiveness of our internal controls and our compliance with legal and regulatory requirements.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and related regulations, the audit committee must consist of at least three directors who meet certain independence criteria. Under the Nasdaq rules, we are
      required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. Each of the members of the audit committee is
      required to be &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1)&#160;under the&#160;Exchange Act.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; color: #000000;">The members of the audit committee are Claude Nicaise (subject to his reelection as a Class II director at the Meeting), Jill Quigley, and Alan Moses. Claude Nicaise is the current
          chairperson of the audit committee, and Jill Quigley is a financial expert under the rules of the SEC. Our Board has concluded that the composition of the audit committee meets the requirements for independence under the rules and regulations of
          Nasdaq and the SEC. During fiscal year 2022, the audit committee held 5 meetings.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Compensation Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under both the Companies Law and Nasdaq rules, we are required to establish a compensation committee.&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The responsibilities of a compensation committee under the Companies Law include recommending to the Board, for ultimate shareholder approval by a special majority, a policy
      governing the compensation of directors and officers based on specified criteria, reviewing modifications to and implementing such compensation policy from time to time, and approving the actual compensation terms of directors and officers prior to
      approval by the Board.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with U.S. law and Nasdaq requirements, our compensation committee is also responsible for the appointment, compensation and oversight of the work of any compensation
      consultant, independent legal counsel and other advisors retained by the compensation committee.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Companies Law and related regulations require the appointment of a compensation committee that complies with the requirements of Nasdaq. Under Nasdaq rules, we are required to
      maintain a compensation committee consisting of at least two independent directors; each of the members of the compensation committee is required to be independent under Nasdaq rules relating to compensation committee members, which are different
      from the general test for independence of board and committee members.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The members of the compensation committee are Nissim Darvish and Neil Cohen (subject to his reelection as a Class II director at the Meeting). Nissim Darvish is the chairperson of
      the compensation committee. Our Board has determined that each member of the compensation committee is independent within the meaning of the independent director guidelines of Nasdaq and under Rule&#160;10C-1&#160;under the&#160;Exchange Act. During fiscal year
      2022, the compensation committee held 5 meetings and conducted certain business by unanimous consent.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Corporate Governance and Nominating Committee</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; color: #000000;">We have established a corporate governance and nominating committee, responsible for making recommendations to the Board regarding candidates for directorships and the size and
        composition of the board. In addition, the committee is responsible for overseeing our corporate governance guidelines and reporting and making recommendations to the board concerning corporate governance matters. Under the Companies Law,
        nominations for directors may also, under certain circumstances, be made by shareholders in accordance with the conditions prescribed by applicable law and our Articles of Association.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The members of the corporate governance and nominating committee are Neil Cohen (subject to his reelection as a Class II director at the Meeting) and Nissim Darvish. Neil Cohen is
      the chairperson of the corporate governance and nominating committee. Our Board has determined that each member of the corporate governance and nominating committee is independent within the meaning of the independent director guidelines of Nasdaq.
      During fiscal year 2022, the corporate governance and nominating committee held 1 meeting and conducted certain business by unanimous consent.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Board Diversity</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">While we do not currently have a formal diversity policy with respect to Board composition, the Board believes it is important for the Board to have gender, race and ethnicity
      diversity along with diversity of knowledge base, professional experience and skills. The corporate governance and nominating committee takes these qualities into account when considering director nominees for recommendation to the Board. We believe
      diversity enhances our effectiveness. While our Board currently has two female directors, the Board remains committed to achieving a Board composition that represents a diversity of background and experience, inclusive of race, ethnicity, gender and
      sexual orientation.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z80c4601ba3ba4351a7758546e9f5d000" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 100%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;" colspan="9">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">TOTAL NUMBER OF DIRECTORS - 6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Female</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Male</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Nonbinary</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">Did Not Disclose Gender</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">PART 1: <font style="font-weight: bold; font-style: italic;">Gender Identity</font></div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Directors</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">2</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">4</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 12pt; line-height: 1.25;">PART 2: <font style="font-weight: bold; font-style: italic;">Demographic Background</font></div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">African American or Black</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Alaskan Native or Native American</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Asian</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Hispanic or Latinx</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Native Hawaiian or Pacific Islander</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Middle Eastern or North African</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">White</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">2</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25;">4</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Two or More Races or Ethnicities</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">&#160;</td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">LGBTQ+</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 8.13%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 5.89%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.49%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 26.28%; vertical-align: middle;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48.22%; vertical-align: top; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="text-indent: -12pt; margin-left: 24pt; line-height: 1.25;">Did Not Disclose Demographic Background</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 7.43%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 5.19%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 10.79%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 0.7%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 25.58%; vertical-align: bottom; background-color: #CCEEFF; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Communication with our Board</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders may communicate with the Board by directing their communications in a hard copy (i.e., non-electronic) written form to the attention of one or more members of the
      Board, or to the Board collectively, at our principal executive offices located at Kiryat Atidim, Building 7, Tel Aviv, Israel 6158002. Any communications received from interested parties in the manner described above will be collected and organized
      by our Corporate Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) and will be periodically, but in any event prior to each regularly-scheduled Board meeting, reported and/or delivered to the appropriate director
      or directors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">For more information regarding our Board, its committees and our corporate governance practices, see Part III, Item 10 &#8220;Directors, Executive Officers and Corporate Governance&#8221;
      of our Annual Report.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL 1</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE-ELECTION OF CLASS II DIRECTORS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Our Board currently has six directors and is divided into three classes with staggered three-year terms as follows:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z41990c09cf33442198a5852429628039" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">
            <div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Class I consists of Nissim Darvish and Jill Quigley, each with a term expiring at the 2025 annual meeting of shareholders.</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z8ecb335d5fad49d4a0f3c25d32e9cd7b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">
            <div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Class II consists of Neil Cohen and Claude Nicaise, each with a term expiring at the Meeting.</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z8c8999ee1e71415fba05b17cbf069d9c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 5%; vertical-align: middle;">
            <div style="text-indent: -18pt; margin-left: 36pt; line-height: 1.25;">&#8226;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Class III consists of Adi Mor and Alan Moses, each with a term expiring at the 2024 annual meeting of shareholders.</font></div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class will
        be for a term of office that expires on the date of the third annual general meeting following such election or re-election.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Meeting, shareholders will be asked to re-elect Claude Nicaise and Neil Cohen. Claude Nicaise and Neil Cohen each qualify as an independent director under the listing
        standards of the Nasdaq. Claude Nicaise serves as a member of our audit committee. Neil Cohen serves as a member of our compensation committee and corporate governance and nominating committee.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">If re-elected at the Meeting, each of&#160;Claude Nicaise and Neil Cohen&#160;will serve until the 2026 annual general meeting of our shareholders, and until their respective successors
        have been duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the Companies Law.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In accordance with the Companies Law, each of&#160;Claude Nicaise and Neil Cohen&#160;has certified to us that he meets all the requirements of the Companies Law for election as a
        director of a public company, and possesses the necessary qualifications and has sufficient time to fulfill his duties as a director of the Company, taking into account the size and special needs of the Company.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">During 2022, each of the directors standing for re-election at the Meeting attended 100% of our Board and Board committee meetings, as applicable.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The corporate governance and nominating committee of our Board recommended that each of Claude Nicaise and Neil Cohen be re-elected at the Meeting as a Class II director for a
        term to expire at the 2026 annual general meeting of our shareholders, and until their respective successors have been duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the
        Companies Law. Our Board unanimously approved this recommendation.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Biographical information concerning&#160;Claude Nicaise and Neil Cohen&#160;is set forth below:</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">Claude Nicaise, MD</font>&#160;has served on our Board since March 16, 2021. Dr. Nicaise is a physician with extensive U.S. and international
      experience in clinical drug development, strategic management, worldwide regulatory strategy, pharmaceuticals, biotechnology, including clinical cancer research, infectious diseases and neuroscience. Dr. Nicaise is the owner and founder of Clinical
      Regulatory Services, which provides consulting services to the life science and biotechnology industry in support of all aspects of clinical and regulatory development. Since 2015, Dr. Nicaise has served on the board of directors and as the Chairman
      of the Compensation Committee of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Dr Nicaise has also served on the board of directors of Mynoryx Therapeutics since 2017. Prior to that time, from 2008 to 2014, Dr. Nicaise served as the Senior Vice
      President of Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), and between 1984 and 2008, he held numerous senior management roles at Bristol Myers Squibb (NYSE: BMY). Dr. Nicaise holds an MD and a degree in Internal Medicine, Clinical Oncology, from
      Brussels University, Belgium.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"><font style="font-style: italic;">Neil Cohen</font>&#160;has served as a member of our Board since April 2020 and served as our interim Chief Executive Officer from October 2020
      until the Chemomab Ltd.-Anchiano Therapeutics Ltd. merger that was consummated on March 16, 2021. Mr. Cohen has served as the Chairman and Chief Executive Officer of Castel Partners Ltd. since January 2012. In 1994, he co-founded Israel Seed
      Partners, a leading venture capital firm, and managed the firm until 2019. Mr. Cohen has invested in and served on the boards of directors of many private technology companies, including a large number which were acquired or completed successful
      initial public offerings, including Compugen (Nasdaq: CGEN), Shopping.com (Nasdaq: SHOP, acquired by EBAY), Broadlight (acquired by Broadcom, Nasdaq: AVGO) and Cyota (acquired by RSA). He is a venture partner at SKY, an Israeli middle-market private
      equity firm, Hetz Ventures Management Ltd., an early-stage Israeli venture capital fund, and Shavit Capital. Mr. Cohen was previously the Business Editor of The Jerusalem Post and began his career in the private equity group at N M Rothschild &amp;
      Sons Limited in London. Mr. Cohen received a B.A. and M.A. in Oriental Studies, with first class honors, from Oxford University.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolutions:<font style="font-weight: bold;">&#160;</font>&#160;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,<font style="font-weight: bold;">&#160;</font>to re-elect Mr. Neil Cohen to serve as a director of the Company to hold office until our 2026 annual
      general meeting of shareholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.&#8221;</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,<font style="font-weight: bold;">&#160;</font>to re-elect Dr. Claude Nicaise to serve as a director of the Company to hold office until our 2026 annual general meeting of
        shareholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.&#8221;</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Meeting in person or by proxy and voting on the foregoing resolution is required. Each director
      nominee shall be voted separately.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 1.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL 2</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TO APPROVE AN AMENDMENT TO THE TERMS OF COMPENSATION OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">DR. ADI MOR AS CHIEF EXECUTIVE OFFICER OF THE COMPANY</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Background</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law, any arrangement between a company and its chief executive officer as pertaining to his or her terms of engagement and compensation must be
        consistent with such company's compensation policy and must be approved by the compensation committee, the board of directors and the shareholders, as described under &#8220;<font style="font-style: italic;">Vote Required for Approval of Each of the
          Proposals</font>&#8221; above, in that order.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The proposed amendment to the terms of compensation Dr. Adi Mor in connection with her appointment as our Chief Executive Officer were approved first by our compensation
        committee and then by the Board, while considering, among other factors, a comprehensive benchmarking analysis prepared and provided by a third-party consultant, Dr. Mor&#8217;s significant ongoing performance and contributions to the Company in her
        capacity as a co-founder, Chief Scientific Officer and member of the Board, measures to incentivize Dr. Mor to continue her exemplary performance now in the role of Chief Executive Officer, the terms and limitations of our Compensation Policy, and
        other factors as required by the Companies Law.</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Accordingly, it is proposed to approve the following amendments to Dr. Mor&#8217;s terms of compensation as our Chief Executive Officer, effective June 1, 2023 (which
      changes are within the limits established in our Compensation Policy):</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">An increase in her annual salary from $247,500 (plus standard Israeli social benefits) to $300,000 (plus standard Israeli social benefits). Her target bonus
      percentage (45% of her annual salary) would not change and she would continue to be entitled to the same car allowance and car expenses.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Dr. Mor would be granted options to purchase 438,870 ADSs (representing 3.0% of the current fully diluted capitalization of the Company) under the Chemomab
      Therapeutics Ltd. 2017 Equity-Based Incentive Plan, as amended from time to time, and/ or under the Chemomab Therapeutics Ltd. 2015 Equity-Based Incentive Plan, as amended from time to time. Such options would vest over four years, provided that upon
      a change in control of the Company, (1) 66% of such options shall accelerate and become vested and exercisable immediately and (2) additional 34% shall become vested and exercisable one year after the date of Board approval of the grant or if within
      one year of the consummation of the change in control, Dr. Mor&#8217;s service is terminated not for cause or she terminates it for &#8220;Good Reason&#8221;. In addition, the period in which she may exercise any of such vested options will be extended from three to
      12 months in the event of a change in control.</div>
    <div><br>
    </div>
    <div style="line-height: 1.25;"></div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For the avoidance of doubt, the foregoing amendment to Dr. Mor&#8217;s terms of compensation is not related to Dr. Mor&#8217;s service as a Class III director of the Company and is
        exclusively in connection with her appointment as the Company&#8217;s Chief Executive Officer and continued service as the Company&#8217;s Chief Scientific Officer.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">All other terms shall remain unchanged. For further information on the compensation terms of Dr. Adi Mor, please see Part III, Item 11 &#8220;Executive Compensation&#8221; of our Annual
        Report.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The shareholders vote on this matter is binding under Israeli law and not merely advisory. If this proposal is not approved by the requisite majority set forth under &#8220;<font style="font-style: italic;">Vote Required for Approval of Each of the Proposals</font>&#8221;, the Company will not be authorized to implement the Dr. Mor Compensation Changes as described in this proxy statement.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolution:<font style="font-weight: bold;">&#160;</font>&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">&#8220;RESOLVED</font>, to approve an amendment to the terms of compensation for Dr. Adi Mor in connection with her role as the Company&#8217;s Chief Executive Officer.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Required Vote</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; color: #000000;">See &#8220;<font style="font-style: italic;">Vote Required for Approval of Each of the Proposals</font>&#8221; in this proxy statement.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Board Recommendation</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 2.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL 3</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">APPROVAL OF AMENDMENTS TO COMPENSATION TERMS OF NON-EXECUTIVE DIRECTORS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Background</div>
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: normal;">As approved by our shareholders, and as required by the Companies Law, we have adopted a
          Compensation Policy regarding the terms of office and employment of our &#8220;office holders&#8221; (as defined in the Companies Law), including cash compensation, equity-based awards, releases from liability, indemnification and insurance, severance and
          other benefits. The Company compensates its directors and senior management team in accordance with the recommendation of its compensation committee, which is subject to the approval of our Board and, oftentimes, the shareholders. Such terms of
          compensation will generally need to be consistent with the terms of our Compensation Policy, which will require periodic approval, in accordance with the requirements of the Companies Law. For a further discussion of our Compensation Policy,
          including the cash and equity grant components specifically, please see Part III, Item 11 &#8220;Executive Compensation&#8221; of our Annual Report.</div>
      </div>
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to the Compensation Policy, on March 15, 2021, our shareholders approved certain actual compensation terms applicable to our current and future directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Director Compensation Package</font>&#8221;), pursuant to which (and among other terms) (i) our non-executive directors (other than the chairperson) are entitled to receive an annual option grant of up to
        0.05% of the Company&#8217;s share capital on a fully diluted basis, (ii) the chairperson of our Board is entitled to receive an annual option grant of up to 0.1% of the Company&#8217;s share capital on a fully diluted basis and (iii) our non-executive
        directors (other than the chairperson) are entitled to receive an annual cash fee of $35,000. The Director Compensation Package implements terms for actual equity compensation that will be granted to directors on a regular basis and determines the
        annual cash fee that may be paid to non-executive directors. In accordance with the Companies Law, equity grants to our directors that are within the limitations of the Director Compensation Package require the approval of our compensation
        committee and Board, but not our shareholders, while any contemplated compensation made in excess of the Director Compensation Package will require the approval of our shareholders. Furthermore, any such compensation, including the annual cash fee
        payable to our non-executive directors, must be limited to the framework of the Director Compensation Package.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; color: #000000;">Our compensation committee and Board believe it would reflect good corporate governance and would serve in the best interests of the Company to amend the Director
        Compensation Package such that the upper limit associated with certain equity-based and annual cash-based compensation to our current and future directors will be consistent with the limitations previously approved by our shareholders in connection
        with the Compensation Policy. In light of the foregoing, our Board recommends that our shareholders approve an amendment to the actual Director Compensation Package whereby (i) future actual annual equity grants to our directors (other than
        chairperson) will be 0.06% of the Company&#8217;s share capital on a fully diluted basis (instead of current annual actual equity grant of 0.05% of the Company&#8217;s share capital on a fully diluted basis), and (ii) our non-executive directors (other than
        the chairperson) shall be entitled to receive an actual annual cash fee of $40,000 (instead of current actual annual cash fee of $35,000).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, it is proposed that the annual payments to our directors (other than the chairperson) for participating in committees shall be modified as follows:</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="2" border="0" id="z292e277c926a4391bf6a6acf85894cc7" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Annual cash payment to Chair Committee</div>
              </div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Current - USD</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed - USD</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Audit Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">15,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">15,500</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Compensation Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">10,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">11,000</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Governance &amp; Nominating Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">8,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">9,000</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Annual cash payment to Committee Members</div>
              </div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Audit Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">7,500</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">7,625</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Compensation Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">5,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">5,500</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Governance &amp; Nominating Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">4,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">4,500</div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;In evaluating the current Director Compensation Package, our compensation committee and our Board considered, among other factors, the desire to align the compensation terms and
        equity incentives of our current members of the Board with those of our peer companies and emerging market trends generally, and specifically received and reviewed relevant benchmarking analysis from a third-party consultant.&#160;In addition, in making
        this recommendation, our compensation committee and our Board considered the compensation&#160;philosophy and applicable guidelines set forth in our Compensation Policy. Our compensation committee and Board concluded that the proposed compensation terms
        would appropriately align the long-term interests of our non-executive directors with those of our shareholders to continue contributing to our Company's success, while ensuring consistency with market practices.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolutions:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED,</font><font style="font-weight: bold; font-style: italic;">&#160;</font>to approve the amendments to the Director Compensation Package, effective immediately, such that (i)
            future annul equity grants to our directors (other than the chairperson) will be 0.06% of the Company&#8217;s share capital on a fully diluted basis (ii) our non-executive directors (other than the chairperson) shall be entitled to receive an annual
            cash fee of $40,000 (iii) the annual payments to our directors (other than the chairperson) for participating in the Board committees shall be modified as follows:</div>
        </div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="2" border="0" id="z8bed57d387304817be93b702ff286fcb" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Annual cash payment to Committee-Chair</div>
              </div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Current - USD</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Proposed - USD</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Audit Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">15,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">15,500</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Compensation Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">10,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">11,000</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Governance &amp;Nominating Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">8,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">9,000</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Annual cash payment to Committee -Member</div>
              </div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Audit Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">7,500</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">7,625</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Compensation Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">5,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">5,500</div>
            </div>
          </td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 47.78%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Governance &amp; Nominating Committee</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">4,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="width: 10%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="line-height: 1.25;">
              <div style="text-align: center; line-height: 1.25;">4,500</div>
            </div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Required Vote</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Meeting in person or by proxy and voting on the foregoing resolution is required.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Board Recommendation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 3.</div>
      <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL 4</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE-APPOINTMENT OF INDEPENDENT AUDITORS</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">AND AUTHORIZATION OF THE BOARD TO FIX THEIR REMUNERATION</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law and our Articles of Association, the shareholders of our Company are authorized to appoint the Company&#8217;s independent auditors. Under our Articles of Association, our Board (or
        a committee, if it is so authorized by the Board) is authorized to determine the independent auditor&#8217;s remuneration. In addition, the approval by our audit committee of the independent auditor&#8217;s re-appointment and remuneration is required under the
        listing rules of the Nasdaq. Following the recommendation by our audit committee and Board, it is proposed that Somekh Chaikin, a member of KPMG International (&#8220;<font style="font-weight: bold; font-style: italic;">KPMG</font>&#8221;), be reappointed as
        the independent auditors of the Company for the fiscal year ending December 31, 2023.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Fees Paid to the Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth fees billed to us by our independent registered public accounting firm during the fiscal years ended December&#160;31, 2022 and 2021 for (i)&#160;services
      rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii)&#160;services by our independent registered public accounting firm that are reasonably related to the performance of the audit or review
      of our financial statements and that are not reported as audit fees; (iii)&#160;services rendered during the period in connection with tax compliance, tax advice and tax planning; and (iv)&#160;all other fees for services rendered.&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z9a2d701bb68e4511b5aa6645923ba1ee" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25;"><br>
              &#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Year Ended</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">December 31,</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> 2022</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2021</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 76%;">
            <div style="text-align: justify; line-height: 1.25;">Audit Fees</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">223</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">173</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25;">Tax Fees</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">30</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">29</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 76%;">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Total</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-weight: bold;">253</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-weight: bold;">202</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">* In USD thousands</div>
      <div style="line-height: 1.25;">&#160;&#160;</div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Auditor Independence</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">
      <div style="text-indent: 36pt; line-height: 1.25;">
        <div style="text-indent: 36pt; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;">In 2022, there were other tax related professional services provided by KPMG that were reviewed and approved by our audit committee in order
          to consider their compatibility with maintaining the independence of KPMG.</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our audit committee has the sole authority to approve the scope of the audit and any audit-related services, as well as all audit fees and terms. The audit committee must
        pre-approve any audit and non-audit services provided by our independent registered public accounting firm. The audit committee will not approve the engagement of the independent registered public accounting firm to perform any services that the
        independent registered public accounting firm would be prohibited from providing under applicable laws, rules&#160;and regulations, including those of self-regulating organizations. The audit committee will approve permitted non-audit services by our
        independent registered public accounting firm only if it determines that using a different firm to perform such services will be less efficient or cost-effective. The audit committee reviews and pre-approves the statutory audit fees that can be
        provided by the independent registered public accounting firm on an annual basis.</div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-weight: bold;">Proposed Resolution</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Shareholders are being asked to adopt the following resolution:</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; color: #000000;">&#8220;<font style="font-weight: bold;">RESOLVED</font>, to approve and ratify the re-appointment of Somekh Chaikin, a member of KPMG International, as the independent auditors of the Company for the fiscal
          year ending December 31, 2023.&#8221;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Required Vote</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The affirmative vote of the holders of a majority of the shares represented at the Meeting in person or by proxy and voting on the foregoing resolution is required.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;">Board Recommendation</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Our Board recommends a vote &#8220;FOR&#8221; Proposal 4.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PRESENTATION AND DISCUSSION OF AUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition to considering the foregoing agenda items at the Meeting, we will also present our audited consolidated financial statements for the fiscal year ended December 31,
      2022. A copy of the Annual Report, including the audited consolidated financial statements for the year ended December 31, 2022, is available for viewing and downloading on the SEC&#8217;s website at www.sec.gov as well as on the &#8220;<font style="font-style: italic;">Investor Relations</font>&#8221; section of our Company&#8217;s website at <u>https://investors.chemomab.com/</u>.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OTHER BUSINESS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board is not aware of any other matters that may be presented at the Meeting other than those described in this proxy statement. If any other matters do properly come before
      the Meeting, including the authority to adjourn the Meeting pursuant to Article 30 of the Articles of Association, it is intended that the persons named as proxies will vote, pursuant to their discretionary authority, according to their best judgment
      in the interest of the Company.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADDITIONAL INFORMATION</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Annual Report filed with the SEC on March 20, 2023, and other filings with the SEC, including reports regarding the Company&#8217;s quarterly business and financial results, are
      available for viewing and downloading on the SEC&#8217;s website at www.sec.gov as well as under the &#8220;<font style="font-style: italic;">Investor Relations</font>&#8221; section of the Company&#8217;s website at&#160;<u>https://investors.chemomab.com/</u>.&#160; Shareholders may
      obtain a copy of these documents without charge at&#160;<u>https://investors.chemomab.com/</u>.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company is subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers. The Company fulfills these requirements by filing
      reports with the SEC. The Company&#8217;s filings with the SEC are available to the public on the SEC&#8217;s website at www.sec.gov. As a foreign private issuer, the Company is exempt from the rules under the Exchange Act related to the furnishing and content
      of proxy statements. The circulation of this proxy statement should not be taken as an admission that the Company is subject to those proxy rules.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z4ce6a05cd77f42d28199f18cdcf9e616" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">By Order of the Board of Directors</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">/s/ Dr. Nissim Darvish</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.9%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 50.1%; vertical-align: top;">
            <div style="line-height: 1.25;">Chairperson of the Board of Directors&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">Dated: July 3, 2023</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: center;">16<br>
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><br>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>exhibit_99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-align: center; line-height: 1.25;">
          <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
        <div style="text-align: center; line-height: 1.25;">
          <div style="font-weight: bold; text-align: right;"> <u> Exhibit 99.2<br>
            </u></div>
          <div> <br>
          </div>
          <div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
              <div style="text-indent: -64.15pt; margin-left: 86.1pt; line-height: 1.25; font-weight: bold;"><font style="font-size: 12pt; font-weight: bold;">Annual General Meeting </font>
                <div>
                  <div style="line-height: 1.25; font-size: 12pt;"><font style="font-weight: bold;">of Chemomab Therapeutics Ltd. </font></div>
                </div>
              </div>
            </div>
          </div>
          <div>&#160;
            <div style="line-height: 1.25">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="width: 6%;">
                      <div><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Date:</font></div>
                    </td>
                    <td style="width: 94%;">
                      <div>August 7, 2023 </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 6%;">
                      <div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
                        </div>
                      </div>
                    </td>
                    <td style="width: 94%;">
                      <div>See Voting Instruction On Reverse Side.</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="2">&#160;</td>
                  </tr>
                  <tr>
                    <td rowspan="1" colspan="2">
                      <div>
                        <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Please make your marks like this: </font>&#8999;&#160;<font style="font-weight: bold;">Use dark black pencil or pen
                            only</font></div>
                      </div>
                    </td>
                  </tr>

              </table>
            </div>
            <div style="line-height: 1.25">
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="width: 2%;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;</td>
                    <td style="width: 72%;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%;" rowspan="1">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 2%;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;</td>
                    <td style="width: 72%;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;&#160;</td>
                    <td style="width: 8.33%; text-align: center; vertical-align: bottom; font-weight: bold;" rowspan="1">For</td>
                    <td style="width: 8.33%; text-align: center; vertical-align: bottom;" rowspan="1">
                      <div style="line-height: 1.25; font-weight: bold;">Against</div>
                    </td>
                    <td style="width: 8.33%; text-align: center; vertical-align: bottom;" rowspan="1">
                      <div style="line-height: 1.25; font-weight: bold;">Abstain</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 2%; text-align: left; vertical-align: top;">
                      <div>1.</div>
                    </td>
                    <td style="width: 1%;"><br>
                    </td>
                    <td style="width: 72%;">
                      <div>
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="line-height: 1.25">
                            <div>
                              <div style="line-height: 1.25;">
                                <div style="line-height: 1.25;">
                                  <div style="line-height: 1.25;">To re-elect each of Dr. Claude Nicaise and Mr. Neil Cohen as Class II directors, to hold office until the close of the Company&#8217;s annual general meeting of shareholders in 2026, and until
                                    their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Articles of Association or the Companies Law;</div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </td>
                    <td style="width: 1%;" rowspan="1"><br>
                    </td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;"> <br>
                    </td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;"> <br>
                    </td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1"> <br>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;</td>
                    <td style="width: 72%;" rowspan="1">&#160;</td>
                    <td style="width: 1%;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                    <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                  </tr>

              </table>
              <div>
                <table cellspacing="0" cellpadding="1" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td style="width: 2%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 2%;"> 1a.<br>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 69%;">
                        <div>
                          <div style="text-align: justify; line-height: 1.25;">
                            <div style="text-align: left; line-height: 1.25;">Dr. Claude Nicaise</div>
                          </div>
                        </div>
                      </td>
                      <td colspan="1" style="width: 1%;">&#160;</td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;">&#160;&#9744; </td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom; font-weight: normal;">&#9744; </td>
                      <td style="width: 8%;">
                        <div style="text-align: center;">&#160;&#9744; </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 2%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 2%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 69%;" rowspan="1">&#160;</td>
                      <td colspan="1" style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;" rowspan="1">&#160;</td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom; font-weight: normal;" rowspan="1">&#160;</td>
                      <td style="width: 8%;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 2%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 2%;" rowspan="1">1b.<br>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 69%;" rowspan="1">
                        <div style="text-align: left; line-height: 1.25;">Mr. Neil Cohen</div>
                      </td>
                      <td colspan="1" style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;" rowspan="1">&#160;&#9744; </td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom; font-weight: normal;" rowspan="1">&#9744; </td>
                      <td style="width: 8%; text-align: center;" rowspan="1">&#160;&#9744; </td>
                    </tr>
                    <tr>
                      <td style="width: 2%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 2%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 69%;">
                        <div>&#160;</div>
                      </td>
                      <td colspan="1" style="width: 1%;">&#160;</td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;"><br>
                      </td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;">
                        <div style="font-weight: bold;"><br>
                        </div>
                      </td>
                      <td style="width: 8%; text-align: center; vertical-align: bottom;">
                        <div style="font-weight: bold;"><br>
                        </div>
                      </td>
                    </tr>

                </table>
              </div>
              <div>
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;">
                        <div>2.</div>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 72%;">
                        <div>
                          <div style="text-align: justify; line-height: 1.25;">
                            <div style="line-height: 1.25">
                              <div>
                                <div style="line-height: 1.25;">
                                  <div style="line-height: 1.25;">
                                    <div style="line-height: 1.25;">To approve an amendment to the compensation terms of Dr. Adi Mor in connection with her appointment as the Company&#8217;s Chief Executive Officer;</div>
                                  </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </td>
                      <td style="width: 1%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;">
                        <div>&#9744;</div>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;">
                        <div>&#9744;</div>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;">
                        <div>&#9744;</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;Yes</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">No <br>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;</td>
                    </tr>

                </table>
                <div style="font-family: 'Times New Roman',Times,serif; text-align: left;">
                  <table cellspacing="0" cellpadding="1" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                      <tr>
                        <td style="width: 2%;" rowspan="1">&#160;</td>
                        <td style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">a.<br>
                        </td>
                        <td style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 69%;" rowspan="1">
                          <div style="text-align: left; line-height: 1.25;">
                            <div style="text-align: justify; line-height: 1.25;">I hereby confirm that I am NOT a controlling shareholder and I do NOT have a conflict of interest (referred to as a &#8220;personal interest&#8221; under the Israeli Companies Law) in the
                              approval of the proposal</div>
                          </div>
                        </td>
                        <td colspan="1" style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 8%; text-align: center; vertical-align: top; font-weight: normal;" rowspan="1">&#160;&#160; &#9744;</td>
                        <td style="width: 8%; text-align: center; vertical-align: top; font-weight: normal;" rowspan="1">&#160; &#9744;</td>
                        <td style="width: 8%; text-align: center;" rowspan="1">&#160; </td>
                      </tr>
                      <tr>
                        <td style="width: 2%;" rowspan="1">&#160;</td>
                        <td style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 2%;" rowspan="1">&#160;</td>
                        <td style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 69%;" rowspan="1">&#160;</td>
                        <td colspan="1" style="width: 1%;" rowspan="1">&#160;</td>
                        <td style="width: 8%; text-align: center; vertical-align: bottom;" rowspan="1">&#160;</td>
                        <td style="width: 8%; text-align: center; vertical-align: bottom; font-weight: normal;" rowspan="1"><br>
                        </td>
                        <td style="width: 8%; text-align: center;" rowspan="1">&#160;</td>
                      </tr>

                  </table>
                </div>
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1"><br>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;For</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;Against</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;Abstain</td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">3. <br>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="line-height: 1.25;">To approve amendments to the compensation terms of the non-executive members of the Board of Directors of the Company;</div>
                        </div>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#160;&#9744;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#9744; <br>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle;" rowspan="1">&#9744; <br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">&#160;</td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: middle; font-weight: bold;" rowspan="1">&#160;</td>
                    </tr>
                    <tr>
                      <td style="width: 2%; text-align: left; vertical-align: top;" rowspan="1">4.<br>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 72%;" rowspan="1">
                        <div style="text-align: justify; line-height: 1.25;">
                          <div style="line-height: 1.25;">To approve the re-appointment of Somekh Chaikin, a member firm of KPMG International, as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2023 and until
                            the Company&#8217;s next annual general meeting of shareholders, and to authorize the Company&#8217;s board of directors (with power of delegation to its audit committee) to set the fees to be paid to such auditors.</div>
                        </div>
                      </td>
                      <td style="width: 1%;" rowspan="1">&#160;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: top;" rowspan="1">&#9744; <br>
                      </td>
                      <td style="width: 8.33%; text-align: center; vertical-align: top;" rowspan="1">&#160;&#9744;</td>
                      <td style="width: 8.33%; text-align: center; vertical-align: top;" rowspan="1">&#9744; <br>
                      </td>
                    </tr>

                </table>
                <br>
              </div>
            </div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">Authorized Signatures - This section must be </font></div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">completed for your instructions to be executed. </font></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;"> <br>
                </font></div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                    <tr>
                      <td style="width: 50.00%;">
                        <div style="text-align: center;">__________________________________</div>
                      </td>
                      <td style="width: 50%; text-align: center; vertical-align: bottom;">__________________________________<br>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50%; text-align: center; vertical-align: bottom;">
                        <div>
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Please Sign Here </div>
                        </div>
                      </td>
                      <td style="width: 50%; text-align: center; vertical-align: bottom;">
                        <div>
                          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Please Date Above</div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 50.00%;">
                        <div>&#160;</div>
                      </td>
                      <td style="width: 50.00%;">
                        <div>&#160;</div>
                      </td>
                    </tr>

                </table>
                <div>
                  <div style="line-height: 1.25;">
                    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                        <tr>
                          <td style="width: 50.00%;">
                            <div style="text-align: center;">__________________________________</div>
                          </td>
                          <td style="width: 50%; text-align: center; vertical-align: bottom;">__________________________________<br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 50%; text-align: center; vertical-align: bottom;">
                            <div>
                              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Please Sign Here </div>
                            </div>
                          </td>
                          <td style="width: 50%; text-align: center; vertical-align: bottom;">
                            <div>
                              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Please Date Above</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>
                      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                      </div>
                      <div style="line-height: 1.25;">&#8593; Please separate carefully at the perforation and return just this portion in the envelope provided. &#8593; </div>
                      <div style="line-height: 1.25;">&#160;<br>
                      </div>
                    </div>
                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                  </div>
                </div>
                <font style="font-size: 12pt; font-weight: bold;">Annual General Meeting of Chemomab Therapeutics Ltd. </font>
                <div style="line-height: 1.25; font-size: 12pt; font-weight: bold;">to be held on August 7, 2023 </div>
                <div style="line-height: 1.25; font-size: 12pt; font-weight: bold;">For Holders as of July 3, 2023 </div>
                <div>
                  <div style="margin-right: 17.7pt; margin-left: 7.95pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
                    <div><br>
                    </div>
                    <div style="margin-right: 6.25pt; margin-left: 9.85pt; line-height: 1.25;"><img width="23" height="20" src="image00001.jpg">&#160;<font style="font-weight: bold;"><u>MAIL</u></font></div>
                    <font style="font-weight: bold;"><u></u></font></div>
                  <div>
                    <div> <br>
                    </div>
                    <div style="line-height: 1.25;">
                      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                          <tr>
                            <td style="width: 33%;">
                              <div>&#160;</div>
                            </td>
                            <td style="width: 2%; text-align: center; vertical-align: bottom;">
                              <div>&#8226;</div>
                            </td>
                            <td rowspan="1" style="width: 65%;">
                              <div>Mark, sign and date your Voting Instruction Form.</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 33%;">
                              <div>&#160;</div>
                            </td>
                            <td style="width: 2%; text-align: center; vertical-align: bottom;">
                              <div>&#8226;</div>
                            </td>
                            <td rowspan="1" style="width: 65%;">
                              <div>Detach your Voting Instruction Form.</div>
                            </td>
                          </tr>
                          <tr>
                            <td style="width: 33%;">
                              <div>&#160;</div>
                            </td>
                            <td style="width: 2%; text-align: center; vertical-align: top;">
                              <div>&#8226;</div>
                            </td>
                            <td rowspan="1" style="width: 65%;">
                              <div>Return your Voting Instruction Form in the </div>
                              <div>postage-paid envelope provided.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div style="line-height: 1.25;">&#160; <font style="font-size: 12pt;"></font><font style="font-size: 12pt; font-weight: bold;"></font></div>
                    <div style="line-height: 1.25;"><font style="font-size: 12pt; font-weight: bold;">All votes must be received by 12:00 p.m. EST on August 2, 2023. </font></div>
                    <div>
                      <div> </div>
                    </div>
                    <div> <br>
                    </div>
                  </div>
                </div>
                <div style="line-height: 1.25;">
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                      <tr>
                        <td style="width: 45%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 55%;">
                          <div><font style="font-weight: bold;">PROXY TABULATOR FOR</font></div>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 45%;">&#160;</td>
                        <td rowspan="1" style="width: 55%;">
                          <div style="text-align: left; line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(170, 170, 170); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">CHEMOMAB THERAPEUTICS LTD.</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 45%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 55%;">
                          <div style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(170, 170, 170); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">P.O. BOX 8016</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 45%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 55%;">
                          <div style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(170, 170, 170); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;">CARY, NC 27512-9903</div>
                        </td>
                      </tr>

                  </table>
                </div>
                <br>
                <div>
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                      <tr>
                        <td style="background-color: #D4D4D4; border-bottom: 2px solid #000000; border-left: 2px solid #000000; border-right: 2px solid #000000; border-top: 2px solid #000000; width: 25%;">
                          <div>&#160;</div>
                          <div> <br>
                          </div>
                          <div> <br>
                          </div>
                        </td>
                        <td style="width: 75%; padding-bottom: 2px;">
                          <div>&#160;</div>
                        </td>
                      </tr>

                  </table>
                </div>
                <div> <br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                      <tr>
                        <td style="width: 40%;">
                          <div><font style="font-weight: bold;">EVENT #</font></div>
                        </td>
                        <td colspan="1" style="width: 1%; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td style="width: 1.04%; border-top: 2px solid rgb(0, 0, 0);">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 40%;">
                          <div>&#160;</div>
                        </td>
                        <td colspan="1" style="width: 1%; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td style="width: 1.04%; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 18%;">
                          <div>&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 40%;">
                          <div>&#160;</div>
                        </td>
                        <td colspan="1" style="width: 1%; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td style="width: 1.04%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 40%;">
                          <div>&#160;</div>
                        </td>
                        <td colspan="1" style="width: 1%;">&#160;</td>
                        <td style="width: 1.04%; border-right: 2px solid rgb(0, 0, 0);">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 18%;">
                          <div>&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 40%;">
                          <div><font style="font-weight: bold;">CLIENT #</font></div>
                        </td>
                        <td colspan="1" style="width: 1%;">&#160;</td>
                        <td style="width: 1.04%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 40%;">
                          <div>&#160;</div>
                        </td>
                        <td colspan="1" style="width: 1%;">&#160;</td>
                        <td style="width: 1.04%;">
                          <div>&#160;</div>
                        </td>
                        <td style="width: 18%;">
                          <div>&#160;</div>
                        </td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 18%;">&#160;</td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 18%;">&#160;</td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 18%;">&#160;</td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%; border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 1.04%;">&#160;</td>
                        <td rowspan="1" style="width: 40%;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%;">&#160;</td>
                        <td rowspan="1" style="width: 1.04%; border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 18%;">&#160;</td>
                      </tr>
                      <tr>
                        <td rowspan="1" style="width: 40%; padding-bottom: 2px;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 40%; padding-bottom: 2px;">&#160;</td>
                        <td colspan="1" rowspan="1" style="width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">&#160;</td>
                        <td rowspan="1" style="width: 18%; padding-bottom: 2px;">&#160;</td>
                      </tr>

                  </table>
                </div>
                <div>&#160;</div>
                <div>
                  <div>
                    <div style="line-height: 1.25;"> <br>
                    </div>
                    <div style="line-height: 1.25;">Copyright <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#169;</sup> 2023 Mediant Communications Inc . All Rights Reserved</div>
                  </div>
                  <div><br>
                  </div>
                  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div class="BRPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div>
                    <div class="BRPFPageHeader">
                      <table cellspacing="0" cellpadding="0" id="za0c414d325514eb8a09bcbffc9000adf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                          <tr>
                            <td style="width: 100%; vertical-align: top;"><br>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div style="line-height: 1.25; font-weight: bold;"> <br>
                    </div>
                    <div style="line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Chemomab Therapeutics Ltd. </div>
                    <div style="line-height: 1.25">&#160;</div>
                    <div style="line-height: 1.25; text-align: left;">
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Instructions to The Bank of New York Mellon, as Depositary </div>
                      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Must be received prior to 12:00 p.m. EST on August 2, 2023)</div>
                      <div style="line-height: 1.25; text-align: center;">&#160;</div>
                      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The undersigned registered owner of American Depositary Shares hereby requests and instructs The Bank of New York Mellon, as Depositary, to endeavor, insofar as
                        practicable, to vote or cause to be voted the amount of Ordinary Shares or other Deposited Securities represented by such American Depositary Shares of <font style="font-weight: bold;">Chemomab Therapeutics Ltd. </font>registered
                        in the name of the undersigned on the books of the Depositary as of the close of business on <font style="font-weight: bold;">July 3, 2023 </font>at the <font style="font-weight: bold;">Annual General Meeting </font>of the
                        Shareholders of <font style="font-weight: bold;">Chemomab Therapeutics Ltd. </font>to be held on <font style="font-weight: bold;">August 7, 2023 </font>or any postponement or adjournment thereof in respect of the resolutions
                        specified on the reverse.</div>
                      <div style="line-height: 1.25">&#160;</div>
                      <div style="line-height: 1.25; font-weight: bold;">NOTES:</div>
                      <div style="margin-left: 5.6pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
                      </div>
                      <div>
                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2b2e132f981e488e812cc4839b59ed10" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%;">

                            <tr style="vertical-align: top;">
                              <td style="text-align: right; vertical-align: top; width: 27pt;">
                                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold; text-align: left;">1.</div>
                              </td>
                              <td style="text-align: left; vertical-align: top; width: auto;">
                                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Please direct the Depositary how it is to vote by placing an &#8220;X&#8221; in the appropriate box opposite each agenda item.</div>
                              </td>
                            </tr>

                        </table>
                      </div>
                    </div>
                    <div style="line-height: 1.25"> <br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" border="0" align="right" style="width: 60%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

                          <tr>
                            <td style="width: 100%; vertical-align: top;">
                              <div style="margin-left: 1pt; line-height: 1.25;">PROXY TABULATOR FOR </div>
                              <div style="margin-left: 1pt; line-height: 1.25;">CHEMOMAB THERAPEUTICS LTD.</div>
                              <div style="margin-left: 1pt; line-height: 1.25;">P.O. BOX 8016</div>
                              <div style="margin-left: 1pt; line-height: 1.25;">CARY, NC 27512-9903</div>
                            </td>
                          </tr>

                      </table>
                      <div style="line-height: 1.25; clear: both;">&#160;</div>
                    </div>
                    <div style="text-align: left; line-height: 1.25; font-weight: 400;">
                      <div>
                        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
                    </div>
                  </div>
                </div>
                <div><br>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!WH# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^)M
M173-&GE8X^0XK:KRSXUZNUAX<C2)OF=]I%73CS22)EL> :]J$FJ:S-,S%EW'
M%9^,\TW)V[N['FG<CBO=A!*)QSE<3!( ]*4@Y-)R/K2YY-5:Y#;'(2H#J<,#
MD&OHKX/>)QJ&EKILC[I8QDY-?.0SM KT+X0ZH-/\4N';"NNT5QXNFG$VI2U/
MJ&BFHVZ-6]1FG5Y)UA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****  \BOESXP6YA\<3S8X( KZC
MKP;XZZ6L4:7P7YG< FNC#.TR*BNCQ;=EL^M*..*% V@T<$U[<7<XI#0><T^D
MP,4M%R!I/5O6K&F?/JMF@[RBJ_!&*V/">GR7_B6U2-=VR0$UE4E[K-H/4^L_
M#<'V?18$QCY16O4%E'Y5G$GH@J>O"D[L[0HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\ Q8T ZWX:
M(0<Q$O7H%5-3MUNM/FA89#(150=I7$]4?$^TJ7C/!4D4NW:F[UKH_'&B2:+K
MTV$*Q$\5S1)* =J]RE-..AR3C9BXXI2>*%/K1_%@U>YDEJ(5POTKU;X)Z5]H
MUR2Z=,KLXR*\MAB>YG2%!EF.,5]/?"WPZNDZ!%,Z;9F'/%<6+J<JLCHI1/0
M,*!Z4M%%>6=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IKQK(,, 13J* *QL+8G)A7\JD2WBC^X@'T%2T4
M7 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHIA.&)H ?3#*B]6 K,OM:M[-6$C &N
M&U7Q0YE8PR<?6NFEA9U-B'-(]*-Q%_?'YTHGB_OC\Z\5D\2WY;Y9#U]:LV_B
M>[\P%I#CZUO_ &?4%[1'L@8-T.:6N/T7Q1;O&%ED&[ZUU-O=)<QAT.0:Y*M&
M4'9HM.Y/124M8H84444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2$X&:6L[6;]+"PDD<XR"!3C%R=D)NQ
MP?CK73)<M8(W YR*X0#Y.>N:LW\[WEX\SG))-5B#CVK[' X94J:.*I+F'!>:
M",C-'./>A>E>B9"X[4W;QFCG=2G- !M^:G*,\TWG'O29(%)JZ&6;"Y:RO%D!
M. :]FT#45U"P27/S8QBO$ #NR:[?P'JI2[,$C?)C@5X.:8:\>='12GK8]0HI
M <C-+7S9U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'<&#+]X'->L>!M4-U8+"[9D4<U\WFF%Y??1UT9WT.QHHHKQ#H"BBB@ HHHH
M***1CM!)[4 <UXQUY=$TF27< V#Q7RUXCUF77]2DN68_,:]$^,?B)Y=0>PAD
M^Z>1FO(T! S7IX6BN6[.>K*PI3;@9Z4CKDY]:5LFD]Z[8Q.=29H:)J,NDWXN
M%<_(<]:^I/ 'B1=?T&&9F'F$<BODSJ,?G7IGPC\3G3-9^R3R8B?Y4&>]<6*H
MZ71T4Y'TM12(VY%8=QFEKS#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOUC^&B3H\1/I6Q7PU7XV=\=@HHHK,84444 %>2?':<Q>'[8 XW/BO6Z\:_:
MS_8-G_UUK2C\:)EL> @<XIQ'/UIH!( [CK2]SFO<CH<3W#&?EH"XI.>G>G$<
M55R6P*@#Z5&_S#ZT[G 'I0>_OTI="D>]_ ^[+6IML\(M>T5X/\""1=3*>R5[
MQ7BXG^(SMAL%%%%8%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %#5;!+^S:-QFO'-=TF:QU!]B'R_6O<,<8K$UW1H[^V
M950;SWQ7?@<6Z,K/8SG&Z/%01G%&/ES6OJOAR;3F8L#US6-O(Z@U]/2Q,9K0
MY.1H=0?NY[TT'/%-+G/2NEU$E<5KC\\<TX1R3JHA&6)Y J2TM7O'\M0<UW/A
M7PH\-P)YERI'0UP8K&QA!LN%/4T/!WAU(;=;F1<2'UKN ,#%,AB6% J# %25
M\I6JRJ2YF=<59!1116104444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?]P?RKBQJ]Y&]#8GHHHKA-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*#THH/2@#Y4^+W_)0;GZ"N(.-M=M\7Q_Q<&Y^@KB-N5Q7N8=_ND<-7XC0\/\
MZ_8$=?.7^=?9EG_QY0_[@_E7QGX=X\06)_Z;+_.OLRS_ ./*'_<'\JX<=\2.
MBCL3T445PFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2!UH 6BJ
M%[J,=LN=PKF[WQBELQ K:%"<U=(ER2=CLZ*X!?'BL*T;/Q:EPP&15?5JG8.9
M'7455M;R.XC#!ADU:K!IIV904444@"BBB@ HHHH **** "BBB@ HHHH ****
M "L;Q'J*6&G2,6PQ&!6PQVJ3Z5Y7X^U<W%S]B1ONG/%=6$HNK52)E*R.0N+E
M[JX::0Y8FFL3GCI32.,T;_X?2OM*--1BDC@;NQ>=U*/TI<X^;UIA/&!U%5.5
MD%A"Q!R:<IWM@=*T-.TN34FV[2*ZFQ\#-L5C7G5\="GU-(T[G%&WE/(!J-@8
M^&KU%/"&T=.U4+WP,TW(KC69QON7[)V//%;<O'6G+TYK=U#PY)IF7P3VK#Y+
ME6&,5ZM'$QJ(Q<6A,G&*1<T;_F)H#<8KHO=$L0D]>XYKT7P#J[2_Z/*W0<5Y
MWGGZUJ^&[\V.K1\\.P%>=F-#G@S:E*S/<J*9$VZ)6]13Z^09V!1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4'I10>E 'RI\7?\ DH-UG^Z*X?G%=O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA2YAD^Y(I^AJ:LQA1110 4444 %%%% !1110 4444 %%)FEH ***:\BQC+$
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M*?2TT[; 9R:1;H^X*,UH*H5<"EHIN4I;@%%%%2 4444 %%%% !1110 4444
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M'0$UW ((R.E>=.+B[,W3N+1114C"BBB@ JEJFH1:98274QPB=35VN,^*19?
M=^5)!V]::5W83V(_^%CZ0!_KE_.C_A9&CG_ELOYU\IK+<./]<W'O2&2X!QYK
M<^]=RPES'VB/LO0?$-IKT<CVKA@AP<5LUXK\ &D;3[_>Y;YNYKV"_NTL[9I'
M8# [UQRBU+E-HO0IZSKUKHT>ZX<+QWKP[QY\0Y))B+";CV-9/Q%\<2:O=S6L
M;D",E017F^'9AO8G/J:[\/A]+LQG.VAKR^+M5F;+2L3]:C_X2;4@<^8WYUG
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MU21'!)&>#7G5*3@S:,[EZBBBLBPHHHH Y'Q[>&#1]J'#$UY,PQSZ\UVWQ"U
MF^%IVQFN*)W#%?5Y1#EHW..L[L;DGFG8/X4 83-*#VKUWJC)[#3G'O0.E*#W
MI,\8IO8E*XO(%(:4G(H!R,4(;5@YQ[T@SCVI<]Z0G Q2N $$"D /7TY%.+9&
M:$/&*FHKQ&>D>"-=WVJV\[Y<5W8.3GL17@NG7[Z?=+.I/7I7K7A_74U&%=[
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M!W<BOH'1M!@TZV2/RU.T8Z5QUL1RZ(VA"YX_X>^'3A5^TP]NXKL%^'MCY/,
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MUJL5*T":2NSV\=!2T45XYUA1110 4444 %%%% !1110 4444 %%%% !1110
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MTTR[2]L(9U8'>H)Q7C8BGR2.FG*Z+E%%%<YH%17/_'K+_N&I:BN?^/67_<-
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M6N'';(UH;G>4445YIU!0>E%!Z4 ?*GQ>&?B#<_05P_%=Q\7>/B#<^ZBN(V\
M5[F'_AHXJGQ%_P /Y/B&Q]?.7^=>Q_%_Q3Y&CV^FVTF)@!N /;%>-Z.XAU>"
M;^XP-:'C/4CJ^OM<%LKL %9UJ;=1,N$K1,!.02>IY-&Y<&@<#/K4EK9RW=XL
M,:ELGG K9R449\MW<2VA>]D$,0)8FNEM?AUJ\ZB01MM/M7I/@OX8)Y<-](/F
M/.#7LEEIL-M;K'Y:\#TKAJXGL=$8'S5%\-M3\L9B.?I5*Y^&VK"1ML38[<5]
M5_9H?^>:_E36M(6'^K7\JP6)E<ITT?&&IZ+=:+-MN5(.:H,=QR.E?3OC+X>0
MZZ7F"@8YKY^\2Z!+HFHR6_EG8O?%=U&LIZ&4H&*!N ]:=QG;2*<#-*/ODUU6
MNC%G??"_Q*VE:V+>63$3<*,U].VLRW%NDB]"*^)[:9K>[BN5)!1LU]6?#G7%
MUCPU;R%@7QR,UYF+IV=SII2OH=E1117";'@%TYEDS4) SGM1N^7--S\N*_08
MQMH>:PYS2]_:@'O1[4V(3G=1SBEW<YH!R,4[C#G'O0O2C=\U!.!B@0F#NI32
MY[T@.1B@ P?QH[^U&[YJ.^*0;"8.:!TYI2>])G(Q3'N')7%,\L8R:>#@T$\8
MI<J 9Y8_&G;!UQQ2YYH!^7%3R(-1?X<#K2#C@T X.:.]4D.PO/XT=\]J0DYH
M!XQ3L38=SCWIHZ<T;CNS1UXH8"A3]ZD )E4#N:4/QBG1?\?$8_VJSJ? QO5G
MLOA!#'H<8-;]8_AH8TB.MBOA:_\ $D>C'8*^7_C'>N_C.:W+?(H! KZ><X0F
MOE+XL-YGCZY/HM:X7XS.KL<8<XXIHSCFE#'I2D?+7L+8X]A!G\:7JW'2DSW]
M:=T%-A<;SC'>K&F$QZS9-Z2BJ^>]6+4XOK=O1P:BIK%E0=I'V/X?F\_1X'SG
MY16I7-^!Y3-X9MV/I725X$MSO04444@"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ^?_CM<^;)!"#]QZ\9R:]0^,<_F:_)%
MG[K5YD!^E>SA4O9''4>HV0D15]+?!JR,7AF&X(^^O6OFH@OA?4U]8?"V+RO
MMBN.<5CC'[I='8[2BBBO,.D**** "BBB@ HHHH **** "BBB@ HHHH ****
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MI1VJJ2&..*[ZDK(P2N=9\.?"<^LZM'<LFZW4\\5]+:3HUMIENBPH%('85B>
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MH'V[5!?.N0O%?1T:A$"@8P*\S%5&WRG12BDA]%%%<1L%1S1+-&4<9!&#4E%
M'S9\7O"K:?K1OX(]MN1S@=Z\OY*X[U]9_$31$UGPY+&5&5!;-?*$R&&XE0CE
M7*UZV$GS1LSFJK49D8KO?A#>&U\9#<<*4Q7!;>*VO"FH&PU^WE!P2X7]:UKQ
MO!HSINS/L9#N13ZBG57L7\RP@?UC!_2K%>(=H4444 -=PB,YZ 9KY?\ B]J\
MFH^*GAC?,*CI[U]*:O.MOI=S(S8Q&V/RKX[UK46OM8N)FY^=A^M=>%A>5S*H
M]#.3@<]*4@D<4C'' JW86[W5_!"BEBS@'%>I-I1N<MM3T[X-^%FN=2^WW$>8
ML<$CO7T0JA4"CH!@5SG@O0DT/088549*AC72 UXM6;G*YVQT0M%%%9%!1110
M 4444 %)C(P:6BE8#RCXP>$AJ.B_:K6/]\K98@=J^<T5E9E/\)P:^V-3MEN]
M.GA8 [T(KY%\8:2VB>(9[8*0I).:]'!U'?E9A6C=&'P13 ":>.!35.#7IHYH
M[,</O+]:^I?A)G_A"H,^M?+?\2_6OJ3X2'/@J#ZUYN-V-L.=Y1117G'4%!Z4
M4'I0!\I_%[/_  L&Y^@KB1G&#UKM_B]_R4&Y^@KA\_Q5[N'7[M'%5W'1LT>6
M'6F[WD?+G)I-Y)Q1NY)K1H+Z#BIDD5%_B.!7M'PI\#G[0;J^BRA7*Y%<!X!\
M/MKVMI&RG9&0V:^J-)L$TZQCA50,"O.Q51KW4;4XV19M;:.UC$<8PHZ58HHK
MSV;A1110 C ,I!Z&O.OB%X.AU+3WDMX@9CW KT4TUT$B$, <U<)N+NB6KGQ/
MJ.GS:7J,EG,"'0U%M)/%>M?&3PF;*Y_M6!,F1L' KR19,)GN:]BA4YXG+4C:
M5Q!C<R^W%>M_!377MM4DL9G_ '87Y1FO(,G=NKH_!^I-IWB2UD!QYD@!J:\;
MP8Z3LS["!R ?6EJO93+/9Q2*<@J*L5XS.L^>203[48^7%.>/9)MI!R<U^A)J
MQYCT%!&*;U'OFEQSBD P,TP%R-U)T'O1M^:@C(S2&+QG-)U%+CM2 8&:8A<C
M=2=!1M^:@C(S0,#C.: <K2X_AI!P,T"%R-U(>!BC;\U+C=S2;2&(<9S0,%:-
MHSBF@X-)L+#LC-)D8]Z,#.*3;QFA,&/XSGM2#E: .U &!FJ ,C=1P%HV_-28
MXS23U =D=:3/RT8&<4$<4=1]!>,YHB_X^(O7<*/]FEC&+A&]ZBH[18ENCVWP
MZ1_9,6/2M>L7PP=^CQFMJOA:W\1GHH9+_JF^E?)_Q3ROCRYSZ5]9$94BOE7X
MMP[?']SQQMK7"?&14VN<3E=FZ@']W2!?X/2DZ';7L]#BDAPP112?=)%*.12:
M8K <8J:T(^TP#OO%08YV^E2Z>-VJ6R_WI *B7PLM+4^M/ '_ "*MO]*ZFL'P
M?;_9O#UO'_LBMZO"G\3.Y;!1114C"BBB@ HHHH **** "BBB@ HHHH ****
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MB P%4"O!?@AI*W%P=0(YC;%?0->1BI7G8ZJ2T"BBBN8U"BBB@ HHHH ****
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MG%?5OAK1X]$T:&TC PHS7FXRI]DZ:438HHHKSS<**** "BBB@ HHHH ****
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M,8%>]1_AHX:K.C\"Q";Q5 A&>]?6]D-ME"/1!7R=\.1N\9P?2OK.V_X]H_\
M=%>=C'=HZ**T):***XC8**** "BBB@#G_&*>9X?G'^R?Y5\@SX%Y<C_IH?YU
M]@^+3C0;C_</\J^/;@9U"Y_ZZ-_.O2P*,*Q'P%Q7I'P4A+>,UE[;*\W(R,UZ
MQ\$H@-=#^U=&)T@S.EN?1=%%%>*=84444 %%%% !7EWQR4'P:I_Z:"O4:\R^
M-XSX,'_72M:/\1$RV/FEN@ I-PS3P!UI@4;\5[G0X5N?37P4.?!@_P!^O2J\
MT^"?_(F?\#KTNO"K?Q&=T=@J*Y;;;2MZ*:EJMJ)VZ=<'TC/\JS11\F_$6<W/
MBV5\YQQ7,*,G-;'B:7[1K=Q)GG>1^M9*X"XKW*:]PX9OWCK/AI9#4/%ZIC.T
M U]80+L@C7T4"OF7X)(&\;OG_GG7TZ.!7FXIWG8ZJ:T%HHHKE- HHHH ****
M "BBB@ HHHH **** /G+XUZ?Y6M->8X; S7E2D8KWOX[V@71H9^[2@5X(5VG
M'M7KX1WB<=5:W!.)1]:^I_A*0?!<&/6OEA>7!]Z^IOA*,>"H/K66.>B+H[G>
M4445YITA0>E%!Z4 ?*GQ>_Y*#<_05P_&[/:NX^+W_)0;GZ"N(*@+7N4/X:.*
MKN+@.Z(.I.*^I_A39BU\&VX(PU?+M@GF:C:K_>D KZ_\)6HL] MX@/X0:YL<
M_=2-:"T-VBBBO,.@**** "BBB@ HHHH *H:S%YVD74?]Z,BK],E021LA[C%-
M;B>Q\9^)[7[#XAN(,8(:LL_,2*[#XGV@M_'MXH&%KD!PYKVZ+O3..:L[&CX<
MD,/B33L''[Y<U]@P72_9X^?X1_*OCK1\+K]@_P#TU%?44-^OD1_-_"/Y5SUZ
M7.T;4Y6B:GBZR-[I#*HR5YKQ8@^:P'13BOH*ZC$MM(A'52*\/UNS^P:I)$!@
M$DUTY/6LW C$+J9V">E I%8@4HYKZ9;'-T% /2AN>11GO0#D8HMU!;"X.,=Z
M0=*3<<YHR<4 &#NI6Z9HW<9I,\8H 7G&.].@A:255'\1Q30?FK>\(6#:AK01
ME_=J,YKDQE54J;9=--R/0_"ND_8=-0LN)#SFNE'2HXUV*J < 8J2OBJDW.3D
MSO2L%%(*6H&%%%% !1110 8XQ6'KVC1WMHP5 7-;E(>E7";A*Z$U<\%U739-
M+NV20'K5,K7JGB[05O(&N OS"O+G1HG9'&"#TKZO 8KVL-=SCJQ<1BYS1WS3
MCP,^M,YW8KU(NZ,MT7]'G:VU*)U."6&:]QLIA-:QL/05X")#',K#L<U[)X0O
MUO-(CRV6':OF\XHV]\Z:$NAT# TZBBO!.DR-?T>#5=.FCDC#,5.,CO7SCK_P
MVO[6628*0F21Q7U+5#4M-BOX#$RC!]JUIU7 F4;GQK+ITUO-Y3 [LUM:9X)O
M=6QY2G\J]YN?A?97%R9B!G/I71:)X5M](QL4?E72\5H9JE9W.=^'?@Q='TV,
MW,0\X=R*]% P,4*H48 Q2UR3FYN[-4K!1114#"BDR*6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.U%':@#Y,^*2$>/KYO>N/
M.?SKO/BQ%L\8W;X^\:X->1SVKV\/_#1QS^(NZ0?+UJR?^[(#7U_X:F$^AV\@
M[K7QU:R;+R!_1J^M_ <OG>$[1\YRM<F-V-:)TM%%%>>;A1110 4444 %%%%
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M8=Y36-_ !ZU?\0-YWB2]?^\YK/.<_2O>IJT$<<]SI/ $JV_BZSE?HKU].?\
M"4VHP-P_.OD:SO7L+E+A/O*<UNMXYO,YRWYUSUJ"F[FE.31].?\ "56N<;A^
M=)_PE=KG[P_.OF/_ (3F\ZY;\Z3_ (3B\)ZM^=<_U57-.=GT[_PE=K_>'YTH
M\56O]X?G7S#_ ,)Q><\M^=+_ ,)S>#NWYT?5D+G9].#Q7:_WA^=+_P )5:_W
MA^=?,0\<7G/+?G1_PG-YZM0\*@YV?3@\5VI_B'YTO_"56N?O#\Z^8O\ A.+P
M=V_.C_A.;S/5OSH^JJX.;/IP^*[7!.X<>]<G\1M=M[WP;=Q(069>*\0'C>[/
M&6Y]ZK7OBVZOK9K=R=IXJEAE&2%*;L8:J5 SVH/ /OTIV=W'K32,CZ5Z-CG3
MN>]? *3?87P]&%>TUX=^SZ?]%U$?[5>XUX>(_B,[8;!7%_%/_D0K_P#W:[2N
M,^*9QX"O_P#=J*?Q(;V/DY!D#VI6X!I(C2/R:]^&QPR6I[S^S[_R#]0_WZ]L
MKQ/]GW_D'ZA_OU[97AXC^(SMA\(4445B4%%%% !1110!XC\<L_N?]VO"ERM>
M[?'+_EE_NUX0"2,^E>QA%>FCCJ_$*>74_P"T*^P_!7_(IZ?_ -<5KX[_ (E'
MJPK[$\%?\BII_P#UQ%8X[9&E#8Z"BBBO-.@**** "BBB@!&^Z?I7S/\ &K/_
M  DL _V:^F&^Z?I7S-\:2?\ A)83Z+77A/B,ZNQYLPPM:?AK_D/6_KFLW.>/
M6M/PW_R,%O[-7IU?@9RQW/L#1?\ D#VO_7,5?JAHO_('M?\ KF*OUX3W.Y".
M<(Q]!7R]\8KG[5XJCP<[1BOI^8X@D/\ LFOD?X@7)G\43$G[KD5UX-7D9U'H
M<N>3]*M:;$9K^%!W<57Q@5J^&4\WQ%;)CJ:]*II%G)&[E8^N?#R[/#]DOI$*
MTZI:0NW2;9?2,5=KPGN=Z"BBBD 4444 %%%% !1110 4C#*D>M+10!\S?&R
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M;O7G^@:6=2U%$*Y0'.:]IL;9;6V2->PKY[-L2FO9HZ:,>I:HHHKY\Z0HHHH
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M(1@UX*(]W?I7<>!M:,=Q]ED;"]LUWXG+N2',B(3NSU.BD7E0?6EKQC8****
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MZPHHHH **** "D;[I^E+2-]T_2@#X_\ '?/CG4L=I#7.D<_6NA\=DCQSJ?\
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MH?LS@O@GHLNF1WHE!Y:O9*RM(T:+2O,\L ;SS6K7)4ES.YH@KB_BF,^ K_\
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MZR_[AKSCH/D7QUQXFF/^T:YS!VUT?COGQ/,/]HUSF3MKW*'P(X9[G6_#,_\
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M=6_-M&?]D5Y^,^(VH[$M%%%<9L%%%% !1110 4444 %%%% 'B/Q\S_9UJ/\
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M5S_QZR_[AJ6HKG_CUE_W#7GFY\B^./\ D9IA_M&N=!&*Z'QT?^*EF/?<:Y[
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M6TH.,R*/UK[&TV59M.MW4YS&O\J\_&+5&U)Z%NBBBN(V"BBB@ HHHH ****
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ME(Z"BBBO-.@**** "BBB@!&^Z?I7S/\ &L'_ (26 >JU],-]T_2OF?XU$_\
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MKQ).[N=JV"HKG_CUE_W#4M17/_'K+_N&I&?(WCH?\5/,?]HUSFT@5T7CH_\
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M8?M&JVL/4O( 17H2=E<PBKL^B_@YIGV;PM!<%<,XZUZ;6'X3T]=-\/V]NHP
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M?KP91<79G2G<****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG%8BR8;/M7U'X[\%VVJP272QAI\<<5\WZMH5UI-W(+A"JY.,UZM"NI*S.>I
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ME)WK D\46(? D'YU:MM>M+EPB.":T=&:5[$\R9K44@.1D4M9%!1110 4444
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MZ?;1,>1G*[:-K=0"<UU4?@+6-PS WY5T>D_#^[9AYT)Q]*'6CW%R-GF!$S,
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M*%V?+A\/SYC/EMP1VKZN\'P&#PQ8H>HB%5?^$)TW_GDOY5T5M MM;I"@PJ#
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M3V&: *.JZ@MA:M*2,@5Y9K7BM]2RBDC!J_XUUQY;AH87^7/-<7L'4=<\U[^
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M444 %%%% "4M%% !1110 4444 %%%% !1110 G>EHHH **** "BBB@ HHHH
M**** "DI:* "BBB@ HHHH **** "BBB@ I" >M+10!$UM"WWHU/X5']AMO\
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M4OV&V'_+%/RJQ11<");>)/NH!^%2]***0!1110 4444 %%%% !1110 4444
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MR",U)7->!-0.I>%;6X9LDCK72UXS5G8[$%%%%( HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>^C$ME*I[J:\)U2
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M[7%7K.HS:,;!1116!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (:XKQYIOGV/G*N6S7;55O[5+JU>-AG(.*VH5'3FI(F2NCP 9#
MF,]J<?N_C6AKNGOI^J.A&.<U1)'2OM,-452*DC@J1L)M&ZE[9IN#NH(.,UTB
M%VC=2]LTWDTJC'6AA87 SBFXXHP<T"@0X#"UK^%]+_M/5U##Y4^:L<9R$[FO
M3/ FDFVC\]UY(ZUY695^2F[;FE*%V=K;Q"&%4'85+117R+U.\**** "BBB@
MI,4M% ";5]!1@>E+10 4444 %%%% !1110 4444 %%%% !1110 THIZJ*-BC
M^$4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J6I6"7]L8F P:NT4XR<7=!8\F\2>%O[/4R6Z9)/85R0MKK)#1L*
M]]FM(KA<2*&^M8=]X>AD4^7$!^%>OALP<;*1C.GV/(5MY",%349AGSA4)KTE
MO"K=EJU:>&%1\O&*[Y9A!*Z9E&F[GG.D:9<W5X(WC.T^U>G:)X5AL76< ;B*
MV;/2+:!01$ WTK250HP*\C$8Z=31&\::0* H %+117GF@4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1BBB@!,#THP/2EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH[T4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44=Z* "BDR*6@ HHHH **** "BBDR/6@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M K'\8.T>A2,AP:S? +R/ITAD8D[^]4EI<#L:***D".:9((R[G"BHK>]ANO\
M5L#BLSQ4S+HLA0X-8G@AI2C^8Q/S=ZI+2X';T445(!4%Q=Q6PS(P J>N/\;2
M2):'8Q%-*[%)V1T']L6G_/0?G1_;%I_ST'YUY$DUTZ;@[<4XR7?3>U7R:D\Q
M[%;WT-S_ *M@:LUPG@LS%_WC$\]Z[NH:L4@HHHI#*UQ?0VS;9' -0?VQ:?\
M/0?G7'^.)I8[P;'(&VN4CENBF[>U6H75Q7U/7!J]J3CS!^=7(I5E7<IR*\:^
MTW,;J2[5W?AC6Q.5MF.6Q0X:!<ZVBBBH&%%%% !44]PEO'OD.!4M<SXTF:/2
M/D;#9II78,VX-0@N)-D;@M5NO+_"5[+_ &VH=R1MKT\'(S3E&Q,7<6BBBI*"
MBBB@"I/J%O;R[)' :HO[8M/^>@_.N"\:W,T>O!4<@;:PRUV#G>W-6H$WU/6E
MU>U8X$@_.KL<BR+N4Y%>,Q75S!*"SMZUZ'X9UA;R(19R11*%D.^ITM%%%0,*
MAN+F.VCWR-@5-7+^.7=-'!1B#N[4TKNP,V/[9M/^>@_.C^V+3_GH/SKR)9+K
M&X.U2%[L?QM5N!+D>OV^H07+[(W!-6J\\\%>>=3)D9B-O>O0ZAJPT[A1112&
M5I[Z&V.)& J6&9)TWH<BN&\:22I<+L8CFNB\+%CI*ECDU35E<5]3;HHHJ1E6
M>_@MWV2. :GCD65-RG(KS[QA+-'JJ;'(!(KL="W?V:FXY.*IJR%?4TZ***D9
M#<7,=LF^1L"JO]L6G_/0?G61XV:1=*3RR0=W:O.]]V3C>U7&-Q-V/6_[8M/^
M>@_.C^V+3_GH*\C^T7(.#(WYT\-=D9WM5.G8E2N>NQ:G;3/L1P35RO+?##W#
M:I\[,17J*?<'TK-JQ28M%%%(95GOH+=MLC@&IXI5F3>AR#7!>,WE6\38Y'S#
MI75>'2QTF,L<FJ:LKBN:U%%%2,***9*XCC9CV% $<US';C+MBL6]UV%&.V0?
MG7.^)->\UVAC;!'I7,1I<W(^\U;1AW,Y2Z'HUAK\+O\ O)!^=;MO=Q7(S&P-
M>.SP7,"A@S"M_P -Z^;62."4DECCFE.'8:9Z5134;<@;U%.K(L*0G I:KWLH
MAMI)"?NC-"!E>[U2"W#*S@,*Q[?Q#&UX5:0;?K7$ZK?37U^S1N=K''%5Y+*Z
MA7S-S5M&*L9\VIZ];WD5R/W; U8KSGPMK#03K'*Q);CFO15.5!]:SDK,T%HH
MHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\G^-^K-9^'HXHF^9GP17K%?.OQJU/SM8:PS]PYQ6^
M'AS3(J.R/)L93/\ $3DT@8CBE!P<TH(W5[4796..4A.>O>E!^;VI"<G/K2KZ
M53(8K9/2N]^$VJ+IGB8JS;1(-HK@@:N:)</;^(;)E8C]ZN?SKGJ^]$TIO4^T
MHVW1JWJ,T^J>ES?:-/AD]4'\JN5XKT9VH****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 9)&)(RIZ&L5O#5JTC/M&2:W:*+@<
M)XGT>"QTR1D !JOX.TF+4;&1Y!DAL5L^-N=*<56^'O\ R#)?]ZM>;W2+>\:Q
M\,VIQ\HXK8@3RHE0=%&!4M%9W+"BBBD!SWC/_D 2?6L_P$?^)=)_O5?\9_\
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M^'O_ "#)O]ZM;>Y<C[1V=%%%9%A1110!SWC/_D 2?6L[P!QILF/[U:/C/_D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7:0PC+$X(KZB^&GA]=(\/PLZ;92.:\R^&/@=KBXCU"5..N"*^@H8EAB5%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <OXTC:32G"]:K> HFBL) ?[U:OB, V;9J'PF +.3']ZM6_<(^T=%1
M116184444 8'B]&?0I O6L[P'$T>GR9_O5M>(AG2GS5+PB +&3']ZK7PB>YT
M=%%%0,P_%2&319%7K6-X)B:*)P1_%71ZX,Z<^:S/#( 1L#^*KB]"7N=+1114
M%!7(^-8S):8%==7.>)P#!S6E+XB9;' P2W=K%LCR!4OV^_Z9.*TU1>.!TI-B
M[3P.M=7*1%Z$_A2[NY-75)B=I%>AUQ.@*!JR8':NVKEJ+WBX[!111691P?C>
M%I+I"HK>\*(8]+ /K5+Q* ;M<CM6KH'%C^-:/X25N:U<'XUT]I;E;@+T'6N\
MK%\2JITTDCG-3'<;V*W@Z61]+(DZ@X%='7/>%QBS./6NAHEN"V"N4\9DO9>4
M.YKJZY7Q1RRCW%*.X/8D\&6YATL[ASNKIJS-# %B,"M.G+<%L%5[V(2VDBG^
MZ:L4R3_5/]#4]1GFOA^"2V\1/QCDUZ8OW1]*XJQ4#7FP*[5?NCZ5<B8BT445
M!1YIXSMVD\0QE1Z5W>CILL(P?05S'B( ZXF1Z5UMA_QZI]*TE\*(3U+5%%%9
MEA1110 5S/C5#)I('^U735@>*_\ D'+_ +U5#XD*6QYY%->VR!(\A:G^W7^.
MIK4"+@<#I2%%]!76T97LA_A2[NYM:*S$XVUZ*.E<1X<4#6S@?PUV]<U3<U6P
M4445F,9+&)8V0]",5YAKVCS6NKL\*D18S7J59&N1H;-V*C..M7!ZDR/,SK5[
M#\BL<#BHWN+S4D\LDFH[H#>W'>MCPZBM.N0#S6S5E<E'4>#M(^R68FE7$IKJ
MZCA54C4*,#%25SMW+04444AA1110!YOXLA9]?0J/XA7=Z4NVQC'M7+:X =;&
M1W%=98?\>J_2M)?"B5NRU1116904444 <)XO@9[Q"!_$*Z?05"Z9&!61XC ,
MHX[UL:'_ ,@Y*TE\*(6YIT445F6%1S0K-&48<&I** /,_$6ARQZ@[P)\G6L<
M:E?60\L,0!7JVI1H;=B5&<5YCK2J)N!WKHIZ[D2T(DUB^GRA8G/%7=%T6>?4
MEEE0[<YJCIRCSUX[UZAI$2"S0[1FG52BM!+<O0QB.)5'85)117,:!6;K=@E]
MI\BL,D#(K2I",C!H \>,-UI<K-@J<TP:W?O(49CM/ KJ?%Z*LG"@<UR6T>9#
MQ_%74U>*9D]S<T#29;G41/,N0#D5Z7&H5 !V%8VA1J+=3@9Q6T.E8U'J7$6B
&BBLRC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I "\# 2(  A$! Q$!_\0
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BHR0,G Z<UW6CZ8NF6>PD-,YS(P]?3Z"DT3_D')6E0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
